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ABSTRACT
Pharmacokinetics of Albuterol and Butorphanol Administered Intravenously and via a
Buccal Patch.  (May 2003)
Deirdre Faye Vaughan, B.S., Auburn University
Chair of Advisory Committee:  Dr. Dawn M. Boothe
Conventional routes of drug administration have several disadvantages.  The rate
and extent of absorption can vary greatly depending on the drug, its formulation, the
presence of food, drug interactions, first-pass metabolism, and gastrointestinal pH.
Better dosage forms or drug delivery mechanisms could minimize these problems.
The pharmaceutical industry has recognized the need for, and has developed
many new, novel drug delivery systems. Drugs that previously had decreased effective
concentrations can be given by novel routes, reducing the dosing frequency of many
drugs.  Transmucosal drug delivery can result in rapid drug absorption and systemic
delivery.  This study utilized a buccal patch to deliver albuterol and butorphanol.
The purpose of this study was to establish pharmacokinetic parameters and the
bioavailability of albuterol and butorphanol when administered intravenously and
buccally. Three dogs weighing 20 kg were studied.  Each received albuterol and
butorphanol by buccal and intravenous administration.  Blood samples were collected
and analyzed by ELISA.  Values for pharmacokinetic parameters were determined using
non-compartmental modeling.
iv
For albuterol, extrapolated Cmax and Co after buccal and IV administration were
10.28 ± 2.77 and 57.74 ± 9.04 ng/ml, respectively.  Volume of distribution was 2.13 ±
1.30 L/kg and clearance was 4.73 ± 3.91 ml/min/kg.  A significant difference existed
between the disappearance rate constant of buccal and intravenous albuterol
administration. The half-lives of buccal and IV albuterol were 160.96 ± 24.19 and
364.20 ± 115.20 min, respectively.  The bioavailability of buccally administered
albuterol was 35%.
Maximal concentration (Cmax) and Co after buccal and IV butorphanol
administration were 6.66 ± 1.65 and 8.24 ± 5.55 ng/ml, respectively. Volume of
distribution was 27.58 ± 10.14 L/kg and Cl was 137.87 ± 19.55 ml/min/kg.  The half-life
of buccally administered butorphanol was 259.15 ± 33.12 min and 172.12 ± 94.95 min
for intravenous butorphanol.  The bioavailability of buccally administered butorphanol
was 606%.
The buccal patch used in this study achieved systemic concentrations for both
albuterol and butorphanol.  Further studies are needed to determine if therapeutic drug
concentrations can be achieved with the buccal patch and if the patch can result in
clinical efficacy.
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1CHAPTER I
INTRODUCTION
NOVEL DRUG DELIVERY
Many advances have been made in recent years in the area of biopharmaceutical
technology.  The systemic delivery of drugs through novel methods of administration is
one area in which significant changes and improvements have been made.  Conventional
routes of drug administration such as oral, intramuscular (IM), and intravenous (IV)
have, in many cases, been supplanted by the advent of new, novel drug delivery systems.
Consequently, precise control of drug input into the body by a variety of routes is now
possible. Controlled and sustained release formulations have been developed and are
gaining in popularity and medical acceptance.1  Drugs that normally exhibit low
bioavailability after oral administration can be given by a novel route in order to
improve duration of action and efficacy.2  Examples include transdermal systems, such
as patches, which been developed for a number of drugs (e.g. nicotine and fentanyl), and
microencapsulation and liposomal drug preparations.2-4
Advantages of novel drug delivery vary with the system, but major goals include
sustained drug delivery leading to less frequent dosing as well as avoidance of marked
fluctuations in peak and trough plasma drug concentrations during the dosing interval
which often is associated with systemic drug administration.5, 6  Other advantages of
pharmacotherapy utilizing novel delivery include:  bypass of the gastrointestinal tract
______________
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2and hepatic portal system, thus increasing the bioavailability of orally administered
drugs that otherwise undergo hepatic first-pass metabolism; improved patient
compliance due to the elimination of pain associated with injections; administration of
drugs in unconscious or incapacitated patients; convenience of administration as
compared to injections or oral medications; and ready termination of delivery by
detaching the patch.2, 7-11  As a result, novel drug delivery systems have the potential to
greatly improve the efficacy and therapeutic benefit of many existing drugs.
PROBLEMS OF CONVENTIONAL DRUG DELIVERY
Oral drug delivery is the most widely utilized route of administration for the
systemic delivery of drugs.12  The popularity of oral drug administration may be
attributed to ease of administration, as well as the traditional belief that drugs delivered
orally—like food—are well absorbed.12  However, oral drug administration is limited by
many disadvantages.  The rate and extent of absorption can vary greatly depending on
the drug, its formulation, the presence or absence of food in the stomach, drug
interactions, and the pH of gastrointestinal fluids.2  These and other factors contribute to
variability in the amount of drug absorbed among patients.2
Extensive first-pass hepatic metabolism can greatly reduce the bioavailability of
orally administered drugs.2  Drug metabolites formed following first-pass through the
liver may not be as active or as potent as the parent drug (e.g. butorphanol), thus
necessitating the oral dose to be much greater than the parenteral dose required to cause
the same clinical effect.13  For some drugs, such as isoproterenol and albuterol, first pass
3metabolism is so great that therapeutic concentrations cannot be achieved with oral
administration.13
Some patients (e.g. sedated, comatose, or neonatal patients) cannot take
medications orally, and some drugs are not available as oral preparations. Children or
veterinary medical patients may be fractious, or otherwise difficult to medicate orally.
Better dosage forms, or drugs delivered via a novel route could minimize many of these
problems.
Regardless of the route of administration, an appropriate amount of drug must be
absorbed and transported to the site of action in order to elicit a given therapeutic
response.  Drug distribution can also be non-selective, resulting in drug residue
appearing in tissues (e.g. liver and kidney) other than the targeted site of action.  Not
only can drug non-selectivity be wasteful, but it can also contribute to toxicity.2  As a
result, the full therapeutic potential of many drugs cannot be realized by conventional
methods of drug delivery.  In many cases, the use of novel drug delivery systems could
circumvent many of these problems, while still achieving therapeutic drug
concentrations.
TRANSDERMAL DRUG DELIVERY
Drug administration across the dermis, or transdermal drug delivery, is a method
gaining increasing use in both human and veterinary medicine.  Transdermal systems
have been utilized in human medicine for the delivery of a variety of compounds.  In
veterinary medicine, a wide variety of drugs have also been formulated into products
that are applied directly onto the skin. Both insecticides and anthelmintics are formulated
4into topically applied treatments.  Furthermore, the growing interest in post-
operative/traumatic pain control in small animals has led to investigations studying the
pharmacokinetics and clinical application of transdermal administration of fentanyl and
oxymorphone in dogs.14
The skin is an anatomically dynamic structure that varies among subjects and is
affected by a variety of conditions.  Such factors include individual, species, and breed
variation, blood flow and vascular perfusion, degree of environmental exposure, body
temperature, hydration state, and skin integrity; each is able to influence drug movement
across the skin.15  As a result of this variability, it is often not possible to predict an
individual animal’s clinical response to transdermal drug delivery.
Formulations of Transdermal Drugs In Veterinary Medicine
Pesticides are among the most common—and perhaps well-
known—transdermally administered compounds in veterinary medicine.  Dosing forms
include backrubbers, dips, body sprays, and medicated ear tags.16  High volume, diluted
pour-on treatments, and low volume, high concentration “spot-on” formulations are also
available as topical insecticide treatments.  The first topical application of a pour-on
insecticide was reported in 1957 to successfully treat pediculosis in chickens and
sheep.16  Pour-on formulations containing organophosphates have had tremendous
impact in the cattle industry by controlling lice infestations and the cattle grub,
Hypoderma species.16  Examples of spot-on formulations include flea control products
such as imidacloprid, selamectin, and fipronil which have revolutionized pesticide
control in companion animals.
5Iontophoresis is an “active” form of transdermal drug delivery whereby
movement through the skin occurs as a result of an electric current.    Iontophoresis
increases the permeability of the stratum corneum to large and/or charged drugs that are
not able to passively diffuse.  The permeability is increased due to mechanical disruption
of the stratum corneum caused by the low voltage current that is generated.  Other means
of epidermal disruption include ultrasonic (phonophoresis) energy, and high voltage
electrical pulses (electroporation).  Due to the electrically induced breakdown of the
stratum corneum, it may be possible to deliver large molecular weight compounds,
peptides, and oligonucleotides via a transdermal route.17  Iontophoretic technology may
be more appropriate to achieve rapid, immediately effective plasma drug concentrations
that more passive technologies (e.g. transdermal patches) are less suited for.18
Iontophoresis has been examined in veterinary medicine to administer dexamethasone,
ketoconzole, lidocaine, 2% methylene blue, and a novel inotropic catecholamine.19-24
Many of the antibiotics used in veterinary medicine to treat bacterial skin
infections are prepared as topical formulations.  These include sulfonamides,
chloramphenicol, polymyxins, and neomycin.  In fact, antiseptics such as nitrofurazone,
povidone iodine, and chlorhexidine are available only as topical preparations.
Antifungal agents are also formulated into topical medications to treat cutaneous
mycoses.  In addition, glucocorticoids are often found in topical antibiotic or antifungal
preparations, or they may be used alone.
Drugs suspended in gel formulations can also be applied cutaneously and
absorbed through the integument.  Investigations utilizing lecithin based organogels have
6demonstrated their effectiveness in increasing the transport rate of scopolamine and
ketoprofen in the skin.25  These gels—as with other transdermal delivery systems—may
be effective in administering drugs to patients that are unable to take oral medications, or
for drugs that undergo significant first pass metabolism and are not available as oral
preparations.  Other advances in the transdermal delivery of drugs include the use of
supersonic helium to deliver drug particles in powder form at a velocity high enough to
penetrate the stratum corneum.26
The use of transdermal patches in veterinary medicine is rapidly gaining interest
and popularity in clinical use.  Fentanyl is the only drug that is currently available in
patch formation that is widely used in small animal patients at this time.  The primary
challenge in development of these systems is based upon the species variation seen in
skin structure and function.
The Skin:  Physiology and Histology
In addition to being the largest organ in the body, the skin is an actual physical
barrier that protects the body from environmental and chemical insults.  On a
physiological level, the skin is vital to thermal, hormonal, immunologic, metabolic, and
electrolyte regulation.27  The skin is composed of two primary layers separated by a
basement membrane:  an outer epidermis and the underlying dermis.  The junction
between the two layers is formed by raised, undulating ridges, called rete ridges.
Capillaries found in the rete ridges provide the blood supply to the avascular
epidermis.27  Hair follicles, sebaceous, and sweat glands all originate in the dermis
before traversing the epidermal layers.  Beneath the dermis is the hypodermis—or
7subcutaneous layer, which attaches the dermis to underlying muscle or bone.16  The skin
is also a dynamic organ, differing in texture and thickness in various regions throughout
the body.28  For example, although basic skin architecture is similar between all
mammalian species, differences do exist and can impact the rate and extent of TDD.16
For instance, rats, mice, and rabbits have more hair follicles than humans, but lack sweat
glands.16  Also, the presence of hair, fur, or wool must be accounted for when using a
veterinary species to investigate transdermal drug delivery, since these structures can
interfere with drug movement through the skin.16
Histologically, the epidermis is classified as stratified squamous keratinized
epithelium and is comprised of five layers.  The stratum basale is the deepest layer and
consists of a single layer of mitotically active cells, thus is partially responsible for
epithelial cell renewal.27  It is supported by a basal lamina and rests on the dermis.  The
stratum spinosum is the thickest layer of the epidermis, and like the stratum basale,
assists in epithelial cell turnover. The stratum granulosum contains cells that possess
membrane-coating granules.27  These granules are released by exocytosis, forming a
waterproof, lipid barrier that represents one of the protective mechanisms provided by
the skin.  The stratum lucidum is a clear, thin layer of cells that is superficial to the
stratum granulosum.  The outer-most layer of the epidermis is the stratum corneum,
containing many flattened layers of keratinized cells surrounded by lipid bilayers with
hydrophilic regions in between.  The stratum corneum is the major barrier to systemic
delivery of drugs applied to the skin.
8A network of arterial and venous blood vessels is interspersed throughout the
dermis.  This blood flow nourishes both the dermis and epidermis, and is the site of
percutaneous uptake of compounds delivered transdermally.  In humans, blood supply to
the epidermis is provided via two artery types:  a musculocutaneous branch that runs
perpendicular to the skin and supplies the skin and underlying muscle; and a cutaneous
branch that travels parallel to the skin and directly supplies blood to the skin.  Blood
flow rates are believed to be one of the factors affecting passive drug perfusion through
the skin.  Increased flow that occurs with vasodilation, increases systemic delivery of
topically applied drugs, while decreasing local accumulation.  Vasoconstriction has the
opposite effect, decreasing systemic delivery and increasing localized drug.  In addition,
flow rates vary between anatomic sites and the species in question.  For example, the
ventral abdomen of the dog exhibits a blood flow rate of 8.78 ± 1.40 ml/min/100g
tissue.17  In contrast, the humero-scapular joint has a flow rate of  5.51 ± 2.32
ml/min/100g tissue.17  Thus, the anatomic site of drug application can play a critical role
in achieving systemic and therapeutic drug concentrations.
Comparative Anatomy of the Integument
Though minor differences do exist, in general, skin structure and function are
analogous among species.  Avian integument, unlike mammalian skin, contains no skin
glands.17  Aquatic mammals, such as dolphins, have an epidermis that lacks the stratum
granulosum, but possess a thickened, parakeratotic appearing, stratum corneum.17  The
integument of pigs is the most similar to human skin, and is thought to be most valuable
for extrapolation of results into human medicine.17, 29
9Blood flow  to the skin also differs among species.  Dogs and cats lack
musculocutaneous arteries; all vessels involved in cutaneous supply therefore travel
parallel to the skin.  In contrast, the musculocutaneous arteries are the primary vascular
supply to human, ape, and swine integument.17
The barrier function of the skin in food-producing animals is not understood as
well as in humans.  Few investigations have addressed the mechanisms that determine
percutaneous absorption of compounds in these animals.  Studies conducted by Pitman
and Rostas30 have found considerable variability in the barrier function of large animals.
For instance, temperature differences exist between black and white-haired regions, and
climatic changes can induce alterations in sebum output and skin thickness.31  The
variability in skin morphology that exists within breeds further complicates the
interpretation of drug movement across different species.  Other factors complicating
transdermal drug delivery include the presence or absence of hair follicles, wool, body
weight, age, and sex.  Since the role these factors have in drug transport across the
integument is not well characterized, further investigations are needed to determine their
relative import.
Principles of Transdermal Drug Movement
For drug to be delivered transdermally, it must pass through the integument and
into the underlying systemic circulation.   Absorption begins in the epidermis, with the
major barrier being the stratum corneum.  Once the stratum corneum has been
penetrated, drugs can diffuse into the deeper layers of the epidermis and the dermis,
respectively.  At the level of the dermis, the drug is absorbed by blood vessels and
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travels into the systemic circulation.  However, drugs that either do not penetrate the
stratum corneum or that fail to partition out of the vehicle, are removed by physical
exfoliation.17  The vehicle is the medium in which an active drug or chemical is topically
administered.  Drugs must be able to partition out of the vehicle in order to penetrate the
stratum corneum.  Thus, the vehicle must have more affinity for the stratum corneum
that it has affinity for the drug.17  Therefore the nature of the vehicle controls, to a great
extent, the degree of success a particular drug will have in penetrating the integument
and reaching the systemic circulation.
Systemic drug administration is not the intention of all topically applied drugs.
Indeed, most topically applied preparations are meant to accumulate in the epidermis and
exert their effects locally.  Penetration enhancers that can augment drug movement
through the epidermal layers, generally are absent in these formulations.16  A simplified,
schematic view of the fate of topically applied drugs is exemplified in (Fig 1).17
Transdermal absorption of drugs occurs primarily through an intercellular route
through the lipid matrix of the stratum corneum.17, 32  Drugs move by passive diffusion
according to Fick’s Law of Diffusion which states that the steady state of drug flux
across a membrane can be defined as follows:
Flux (J)= DP  (Concentration Gradient) (Surface Area)
   h
where D is the diffusivity of the drug in the intercellular lipids of the stratum corneum, P
is the partition coefficient for the drug between the skin surface and the stratum
corneum, and h is the skin thickness.18  The catalyst for this dynamic process is the
concentration gradient that exists between the applied dose of drug and the degree to
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which the dermis is perfused.18  Transdermal flux is defined in terms of surface area.
Accordingly, the two critical points of transdermal dosage are the concentration of drug
applied, and the surface area at the site of application.18
Figure 1—The fate of topically applied drugs.17
 The ability of a drug to diffuse through the skin is a function of its molecular
weight, molecular interactions with skin components (hydrophobic or hydrophilic
regions), the drug’s solubility, and the degree of drug ionization.  Large molecular
weight drugs exhibit a low degree of diffusivity.16, 18, 32   Only non-ionized fractions of
weak acids or bases are available for passive diffusion across the stratum corneum.18
Absorption through the skin is also dependent on the condition of the skin itself.
The rate-limiting structure of transdermal drug absorption is the stratum corneum,
Drug is applied to skin surface
Drug fails to partition out of vehicle Drug partitions out of 
vehicle into stratum corneum
Drug removed physically via exfoliation No penetration
Penetration into
stratum corneum
Metabolized Not metabolized
         Dermis
                                                                                         Absorbed into systemic circulation
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disruption, injury, or removal of this layer can result in a dramatic increase in
permeability.33
Barriers to Drug Penetration
Although the barrier function of the stratum corneum is essential to maintaining
internal homeostasis, it can be a major impediment to drug penetration.  The stratum
corneum exhibits low permeability, with a relatively uniform thickness of 30 microns
across domestic animal species (Table 1).16
Table 1—Stratum corneum thickness for several species.16
Species Stratum corneum thickness (µm)
Hairless mouse 8.8
Hairless rat 15.4
Guinea pig 18.6
Dog 19.9
Pig 17.5
Human 18.2
Sheep 31.4
Cattle 30.9
Due to the lipid composition of the stratum corneum, lipophilic compounds are
best able to penetrate.32  However, hydrophilic regions in the layer will deter strongly
lipid-soluble molecules.32 As a result, ideal transdermal drugs should have both
lipophilic and aqueous characteristics.  There is also species variation in the amount of
lipid contained within the stratum corneum, a fact that must be considered when
formulating transdermal drugs.34
The structure of the skin guards against penetration of large molecular weight
compounds.  Based on the fact that most of the common contact allergens in human
medicine are below 500 Da, it has been proposed that molecules larger than 500 Da
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cannot effectively penetrate the skin.32  With the exception of few, most drugs
administered topically are also smaller than 500 Da  (Table 2).32
Table 2—Commonly applied transdermal drugs and their molecular weight. 32
Compound Molecular Weight
(Dalton)
Topical antifungals
       Ketoconazole
       Clotrimazole
       Miconazole
531
345
416
Topical Corticosteroids
       Hydrocortisone
       Bethamethasone
       Difflucortolone
404.5
477
394
Topical anti-infectives
       Gentamicin
       Acyclovir
478
225
Transdermal drug-delivery systems *
       Nitroglycerine
       Nicotine
       Fentanyl
227
162
336
Topical parasiticides *
       Fipronil
       Imidacloprid
       Ivermectin
437.15
255.7
875.1
* denotes drugs intended for systemic delivery
The presence, quantity, and type of hair follicles are important considerations
that impact transdermal drug delivery.  Hair density in pigs and humans is considerably
less than that of the rodent.  Other species differences are also important.  Sheep wool is
coated with an emulsion of sweat and sebum that has been reported to act as a solvent
for topically applied chemicals.  This emulsion has been reported to directly compete
and interfere with drug diffusion through the skin.35   Hair follicles, sebaceous, and sweat
glands are often thought to be channels through which compounds can be
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shunted—therefore bypassing the rate-limiting stratum corneum.16  Thus, areas covered
with hair will have a greater skin surface area for transdermal drug absorption to occur.16
Species with high hair density also have reduced interfollicular epidermis, which may
lessen the barrier to drug penetration.18  These are important considerations when dealing
with species that have sparse versus dense hair coats.  In humans, for instance, sweat
gland and hair follicle openings only represent 0.1% of the total skin surface, probably
attenuating their significance in drug delivery.32
The skin also has the ability to metabolize compounds before they are absorbed
systemically.18  Investigations have shown that the epidermis is capable of both phase I
and II biotransformation pathways. 18  Although cutaneous first-pass metabolism utilizes
cellular enzymes and soluble esterases, compared to hepatic metabolism, it has only a
minor role in the metabolism and degradation of drugs. 18
The wide range of body surface areas among and within species impacts drug
movement.  The body mass of humans often only varies by a factor of 2-3 fold. 18
Veterinarians, however, deal with great differences in body size, from laboratory mice to
elephants.  This variability in size can complicate drug administration. In particular, a
single “one size fits all” transdermal patch is both impractical and virtually impossible to
develop for veterinary medicine.  The most important factor in transdermal  patch-based
drug delivery is the ratio of the patch area to total body mass of the animal.18
Transdermal patches are designed to deliver precise amounts of drug directly
proportional to the surface area of the patch. For example, fentanyl is delivered at a rate
of 25 µg per hour per 10cm2 patch.14  Patch sizes sufficient to deliver therapeutic
15
concentrations of a drug via the greater surface area of large animals would be
unrealistic to develop, except for very potent drugs, for which low effective plasma
concentrations are therapeutic—as is the case with pesticides. 18
Enhancing Drug Penetration
Transdermal drug movement can be facilitated with the use of penetration
enhancers or adjuvants included in the drug formulation.16, 34  These substances appear to
increase fluidity in the intercellular lipid of the stratum corneum, and cause the stratum
corneum to swell and/or exude structural components that might otherwise hinder drug
passage.  This causes a change in the permeability coefficient of the lipid relative to the
drug, thereby increasing drug penetration.16, 18  Enhancers include lipophilic compounds
such as ethanol, oleic acid, and terpenes.  Solvents such as dimethyl sulfoxide (DMSO)
with a molecular weight of 78.14 Da, also facilitate the passage of molecules through the
skin.27  Alternative methods to disrupt or alter the stratum corneum are through the use
of ultrasound or iontophoresis.
 The dermis is a vascular structure with its blood supply under complex neural
and local control.  Dermal perfusion varies in regard to body temperature and for certain
compounds, modification of perfusion may alter drug delivery through the skin. 18, 36  For
instance, vasoconstriction will result in decreased dermal perfusion, thereby reducing
systemic absorption, but enhancing local drug activity. 18   Vasodilation, on the other
hand, will increase blood supply to the dermis, maximizing systemic delivery while
minimizing local accumulation.18, 36   This principle is often used in local anesthesia with
the inclusion of a vasoconstrictor, such as epinephrine, in the anesthetic solution.
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Epinephrine decreases local perfusion and thus delays vascular absorption of the
anesthetic, thus prolonging anesthetic action.
Transdermal Patches In Veterinary Medicine
In veterinary medicine, the delivery of drugs through the skin has been widely
employed.  Topical medications have been used locally to treat bacterial infections,
seborrhea, keratinization disorders, and allergic dermatoses.17, 36  Most of these
formulations, however, are used to treat specific, local diseases.  Therapy to achieve
systemic drug concentrations is also commonly utilized—most often in the form of
pesticides.  Several flea, tick, and heartworm preventatives containing fipronil,
imidacloprid, and selamectin are applied to a local area of skin and are widely used and
promoted by veterinarians.  In fact, the veterinary “dermatopharmacologic” industry is
rapidly expanding to include other drugs available for systemic transdermal delivery.  In
anesthesia, transdermal fentanyl patches have been investigated as an alternative route to
deliver opioid analgesic agents.  Because fentanyl provides only short-term analgesia
when administered subcutaneously (SC) or as a bolus IV dose, transdermal patches were
developed to outweigh these limitations.  It has been suggested that one of the
advantages of transdermal systems is that they offer continuous drug release that is
slower than absorption, thereby maintaining a relative constant plasma drug
concentration and prolonging the analgesic interval.15, 37   Because the degree of
analgesia can be maintained for extended periods of time, the disadvantages of frequent
dosing, including resultant fluctuations in peak and trough plasma concentrations can be
avoided.  Also, many analgesics may require large loading doses to attain immediate,
17
effective plasma drug concentrations, thus potentially increasing the risk of toxicosis.15
Additional benefits of transdermally delivered fentanyl include the elimination of
repeated oral doses, avoidance of injection pain, reduction in first pass hepatic clearance,
and a decrease in the equipment and labor costs that accompany a continuous
intravenous infusion.38, 39   However, the animal must be clipped and prepped at the site
of patch application.  Also, some animals may require an Elizabethan collar to prevent
chewing, biting, or scratching the patch, causing terminated or interrupted drug delivery.
In addition, there is some liability in sending a fentanyl patch home with owners due to
the abuse potential of the drug.  Timing is also critical in patch application.  It is
recommended to apply the patch at least 24 hours prior to surgery or expected trauma in
the dog.15
Fentanyl is the only drug available as a transdermal patch and used clinically in
small animals at this time. Transdermal fentanyl systems have four components:  a
protective polyester backing, a fentanyl reservoir, a semipermeable membrane that
controls/limits the rate of drug release, and an adhesive layer.15  The fentanyl patch has
been shown in vivo to demonstrate large variations in delivery rate, plasma drug
concentration, and epidermal drug absorption among dogs.15, 37  Similar
pharmacodynamic variations have also been shown in humans.15  Variation in drug
behavior is also evident among different species.  For example, it often takes 24 to 36
hours to achieve steady state plasma and therapeutic concentrations in dogs following
patch application.6, 15, 40  In horses, however, fentanyl is rapidly absorbed within 4 hours
after application of the patch.40  Studies involving cats have resulted in conflicting
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findings.  In one study, steady state concentrations were reached within 2 to 6 hours
following application of the patch.41  In another study, however, steady state
concentrations were not achieved until after a 12 to 18 hour delay.40
The clinical efficacy of transdermal fentanyl patches has been investigated in
several studies for application in veterinary medicine.  Many evaluate fentanyl patches in
the context of achieving a balanced anesthesia protocol, either alone or in comparison to
other drugs.  In one study, transdermal fentanyl was compared to injectable butorphanol
in cats following ochyectomy.40  The two analgesic protocols were compared using a
pressure-sensitive mat to evaluate post-surgical lameness.  Since the pressure mat was
unable to detect a difference between the two protocols, these results either suggest
analgesic equivalence of transdermal fentanyl and butorphanol or could indicate the
pressure mat was not sensitive enough to identify a difference.40  This study also refuted
earlier claims regarding the economic benefit of using transdermal fentanyl patches as
opposed to other formulations.  In fact, the cost of using transdermal patches in this
investigation was 2.5 times the cost of using butorphanol.40  However, the investigator
did note that the increased cost might be justified by the benefits in using non-invasive
patches, which include ease of application and maintenance, and improved patient
tolerance for patches as opposed to periodic injections and administration of pills.
Another study compared transdermal fentanyl to epidural morphine for analgesic
effectiveness following orthopedic surgery in dogs.14  Heart rate, respiratory rate, body
temperature, and pain score were recorded both pre and post-surgery.  Fentanyl patches
were applied 24 hours prior to surgery.  When variables were analyzed post-surgery, the
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dogs in the transdermal fentanyl group experienced significantly less pain after surgery
than dogs given epidural morphine.14
TRANSMUCOSAL DRUG DELIVERY
The disadvantages of traditional routes of drug administration have led clinicians
and researchers to search for new, novel alternatives in pharmacologic dosing.  As is the
case with the integument, the oral cavity is another example of a novel site for drug
delivery.  The oral mucosa has been investigated in several studies as a means to give
both local and systemic amounts of drug.12  Drug delivery across mucosal membranes,
such as the oral mucosa, is termed transmucosal drug delivery (TMDD).  TMDD can be
divided into three different target areas based on the characteristics of the oral cavity:
(1) sublingual delivery, consisting of administration through the membrane of the ventral
surface of the tongue and the floor of the mouth, (2) buccal delivery, consisting of
administration through the buccal mucosa, mainly composed of the lining of the cheeks,
and (3) gingival delivery, consisting of administration through the gingival mucosa.7
These sites differ anatomically in their permeability to drugs, rate of drug delivery, and
ability to maintain a TMDD system for the time required for drug release out of the
delivery apparatus and into the mucosa.42  This study focuses on the suitability of the
buccal mucosa to deliver systemic drug concentrations.
Transmucosal drug delivery via the buccal lining has proven particularly useful
and offers several advantages over other drug delivery systems including:  bypass of the
gastrointestinal tract and hepatic portal system, increasing the bioavailability of orally
administered drugs that otherwise undergo hepatic first-pass metabolism; improved
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patient compliance due to the elimination of associated pain with injections;
administration of drugs in unconscious or incapacitated patients; convenience of
administration as compared to injections or oral medications; sustained drug delivery;
increased ease of drug administration; and ready termination of delivery by detaching
the patch.2, 8-11  Though less permeable than the sublingual area, the buccal mucosa is
well vascularized, and drugs can be rapidly absorbed into the venous system underneath
the oral mucosa.7, 8, 42, 43  The large contact surface of the oral cavity contributes to rapid
and extensive drug absorption.7, 9, 43  Additionally, mucosal surfaces do not have a
stratum corneum.  Thus, the major barrier layer to transdermal drug delivery is not a
factor in transmucosal routes of administration.
In comparison with transdermal drug delivery systems, TMDD systems exhibit a
faster initiation and decline of delivery than do transdermal patches.8  Also, TMDD
delivery occurs in a tissue that is more permeable than skin and is less variable between
patients, resulting in lower intersubject variability.8  Because of greater mucosal
permeability, TMDD can also be used to deliver larger molecules such as low molecular
weight heparin.8  In addition, TMDD systems could potentially be used to deliver drugs
that exhibit poor or variable bioavailability, and bioavailability will be enhanced for
drugs that undergo significant first-pass metabolism.8, 9, 44  Because drug absorbed from
the oral cavity avoids both first pass metabolism and enzymatic/acid degradation in the
gastrointestinal tract, transmucosal administration could be of value in delivering a
growing number of peptide drugs.42
Buccal Mucosa:  Physiology and Histology
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The various regions (sublingual, buccal, gingival) of the oral mucosa vary
anatomically and physiologically.  Due to these differences in structure as well as
function, considerable variation exists in permeability among these regions.42  This
difference could make one region more or less suitable for delivery of a particular drug.
In addition, just as the microstructure and function of the integumentary system differs
between and within species, the buccal mucosa also exhibits some dissimilarity.
The oral mucosa is comprised of an outer layer of stratified squamous non-
keratinized epithelium.  Below the epithelium lies a basement membrane, a lamina
propria, and submucosa, respectively (Fig 2).  Oral epithelium is very similar to
epithelium found elsewhere in the body.  It consists of a basal cell layer, several
intermediate layers, and a superficial layer from which cells shed.  There are
approximately 40-50 cell layers that make up the buccal epithelium, with a cellular
turnover time of 5-6 days.42  In humans, dogs, and rabbits, the buccal mucosa measures
500-800 µm in thickness.42  Other areas of the oral epithelium (gingiva, hard and soft
palates, floor of mouth) vary in size.  Likewise, the composition of the epithelium varies
in accordance with location.  Areas that endure mechanical stress such as the gingiva and
hard palate, like the epidermis, are keratinized.  In contrast, the buccal mucosa,
sublingual region, and the soft palate are not keratinized.  Large quantities of protein are
present in the cells of both keratinized and non-keratinized epithelium.  Keratinized
regions of the mucosa contain large amounts of acylcermides and ceramide, while the
more permeable non-keratinized mucosal regions (buccal, floor of mouth) contain
smaller quantities of lipid.
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The basement membrane forms the boundary between the lamina propria and the
basal layer of the epithelium.  Composed of collagen, the basement membrane is thought
to provide support and adherence between the epithelium and the lamina propria, and to
form a mechanical barrier to cells and some large molecules across the mucosa.  The
lamina propria lies underneath the basement membrane and consists of a continuous
sheet of collagenous connective tissue and elastic fibers.  The capillaries and nerve fibers
that supply the mucosa are present in this region.
Comparative Anatomy of the Buccal Mucosa
The oral lining of most laboratory animals is a thick, keratinized epithelium.45
This is in contrast to the non-keratinized mucosa of humans, dogs, pigs, monkeys, and
rabbits.45  As a result, the data obtained from the use of laboratory animals in drug
permeability studies is limited in its value, especially in studies that wish to extrapolate
data to either human or other animal species.45  Dogs are frequently used models in
buccal drug delivery investigations due to their non-keratinized buccal mucosa and its
similarity to human mucosa.45
Epithelium
Lamina Propria
Submucosa
Figure 2—Generalized structural components of the oral mucosa.
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CONSIDERATIONS FOR TRANSMUCOSAL DRUG DELIVERY
Nature of Permeant
Drugs administered via the oral mucosa gain access to systemic circulation by
passive diffusion in accordance to Fick’s law.42   Less common is carrier-mediated
transport or facilitated diffusion.42  Most drugs move extracellularly through the neutral
lipids and glycolipids that separate the mucosal cells.  Therefore, the lipid solubility of
drugs is an important determinant in TMDD suitability.
Along with lipid solubility, drugs selected for TMDD must have physiochemical
properties, including size and pKa, that facilitate drug movement through the mucosa at
a rate capable of producing therapeutic blood concentrations.42  The drug must resist, or
be protected by salivary and tissue enzymes that could cause inactivation. 42
Additionally, the drug and adhesive materials must not damage the teeth, oral cavity, or
surrounding tissues  (e.g. by keratinolysis, discoloration, and irritation). 42
Molecular Size
The rate of absorption of hydrophilic compounds is a function of the molecular
size. 42  Smaller molecules (<75-100 Da) generally exhibit rapid transport across the
mucosa, with permeability decreasing as molecular size increases. 42  For hydrophilic
macromolecules such as peptides, absorption enhancers (see later section) have been
used to successfully alter the permeability of the buccal epithelium, causing this route to
be more suitable for the delivery of larger molecules.46  Though the relationship between
permeability and size has not yet been demonstrated for lipophilic substances, based on
previous investigations it is likely such a correlation exists.32, 46   
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Lipid Solubility and Partition Coefficient
Only the nonionized forms of molecules have the ability to cross lipoidal
membranes in significant amounts.45  The more lipid soluble a compound is, the higher
its permeability. 42  The permeabilities for these compounds are direct functions of their
oil-water partition coefficients. 42  The partition coefficient is a useful tool to determine
the absorption potential of a drug.47  In general, increasing a drug’s polarity by
ionization or the addition of hydroxyl, carboxyl, or amino groups, will increase the water
solubility of any particular drug and cause a decrease in the lipid-water partition
coefficient. 47   Conversely, decreasing the polarity of a drug (e.g. adding methyl or
methylene groups) results in an increased partition coefficient and decreased water
solubility.47   The partition coefficient is also affected by pH at the site of drug
absorption.  With increasing pH, the partition coefficient of acidic drugs decreases, while
that of basic drugs increases.47   The partition coefficient is also an important indicator of
drug storage in fat deposits.  Obese individuals can store large amounts of lipid-soluble
drug in fat stores.47   These drugs are dissolved in the lipid and are a reservoir of slow
release from these fat deposits.
Ionization
The ionization of a drug is directly related to both its pKa and pH at the mucosal
surface.42  Only the nonionized form of many weak acids and weak bases exhibit
appreciable lipid solubility, and thus the ability to cross lipoidal membranes.42, 45   As a
result, maximal absorption of these compounds has been shown to occur at the pH at
which they are unionized, with absorbability diminishing as ionization increases. 42
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PRINCIPLES OF DRUG MOVEMENT THROUGH THE BUCCAL MUCOSA
Like transdermal drug movement, drugs contacting the oral mucosa must
penetrate the epithelial barrier in order to gain access to systemic circulation.  The
epithelium represents the primary barrier to compounds, though unlike the epidermis,
there is no stratum corneum present in the oral cavity.
Drug transport across the oral mucosa is achieved by two pathways:  1) the
paracellular (between cells) route, consisting of hydrophilic intercellular spaces, and 2)
the transcellular route, through pores in the cell membranes or penetration through the
lipid bilayers of cell membranes. 42, 45   Hydrophilic compounds, and large or highly polar
molecules, follow paracellular transport, whereas transcellular transport through the lipid
bilayer is followed by lipophilic drugs and by small molecules through epithelial
membrane pores. 42, 45
Buccal patches can potentially deliver a wide range of drug classes (e.g. opioids,
antifungals, hormones) with differing physiochemical properties  (lipophilic,
hydrophilic, 200-10,000 Da), and at various concentrations.42, 48  However, small
lipophilic molecules active at low plasma concentration (e.g. are potent) are the easiest
to deliver.43  As with transdermal drug delivery studies, methods to increase overall drug
permeability and to make a wider selection of compounds available and practical for
buccal delivery are being investigated.
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CHAPTER II
BUCCAL PATCH SYSTEMS
STRUCTURE AND DESIGN
  Drug delivery systems designed for the buccal mucosa contain a polymeric
adhesive component.  When in contact with the saliva, the adhesive attaches to the
mucosa causing immediate and rapid drug delivery.  Transmucosal drug delivery
systems can be unidirectional or bi-directional. 42, 45   Unidirectional patches release the
drug only into the mucosa, while bi-directional patches release drug in both the mucosa
and the mouth.  The buccal patch is designed in either a matrix configuration with drug,
adhesive, and additives mixed together (Fig 3), or a reservoir system that contains a
cavity for the drug and additives separate from the adhesive.42  An impermeable backing
is applied to control the direction of drug delivery; to reduce patch deformation and
disintegration while in the mouth; and to prevent drug loss.42, 49  Additionally, the patch
can be constructed to undergo minimal degradation in the mouth, or can be designed to
dissolve almost immediately.42
Fig 3—Schematic representation of the buccal patch design.
Backing layer
Drug and
mucoadhesive matrix
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 Much less is known about the type and characterization of drug transport that
occurs in the buccal epithelium as opposed to other sites of mucosal drug delivery, such
as the gastrointestinal tract.50   How these drug processes may be altered in disease or
manipulated pharmaceutically in order to optimize drug absorption, is less defined.50
Currently, buccal patches have been used to deliver a variety of drugs to dogs including
buprenorphine, heparin, melatonin, theophylline, nitroglycerine, digoxin, propranolol,
miconazole, insulin, morphine, fentanyl, and estradiol.10, 45, 46, 51-53
HISTORICAL BACKGROUND AND LITERATURE REVIEW
The absorption of drug via the oral mucosa was recognized as early as 1847 in
the investigations of Sobrero, the discoverer of nitroglycerin.42  Later studies ensued with
Overton in 1902 and the first systemic studies of oral cavity absorption were conducted
by Walton in 1935 and 1944.42, 54  The investigations of Walton provided information on
the importance a drug’s lipid solubility and pH have in its transport through the oral
mucosa.53,54  More recently, factors such as drug ionization, improved patch design, and
the use of prodrugs, have all been shown to be important in drug absorption and
delivery.
Numerous in vivo and in vitro experiments have been conducted in an effort to
further define the feasibility of buccal patch drug delivery systems.  These studies have
been important in determining the overall feasibility of developing buccal patch systems
for in vivo drug delivery.  Numerous in vitro investigations have centered on the buccal
patch design itself, in an effort to improve or enhance mucosal drug delivery.  Others
have studied drug flux across mucosal membranes, compared mucosal properties across
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species, or have centered on the effects of pH and penetration enhancers on drug
passage.
Increasing Permeability:  Penetration Enhancers, Prodrugs, Patch design and pH
Penetration Enhancers
In addition to the adhesive component, buccal patches can also incorporate
additives such as solubilizers or penetration enhancers.  Absorption enhancers have
demonstrated their effectiveness in delivering high molecular weight compounds, such
as peptides, that generally exhibit low buccal absorption rates.  Although only a few
buccal enhancement studies have been performed, reports show promising results using
permeation enhancement agents.42  Among these agents are Azone, ionic and nonionic
surfactants, chelators, chitosan, and bile salts.51  Azone is a type of accelerant that
interacts with lipids in the stratum corneum in order to increase fluidity in the
hydrophobic regions of intercellular areas, thus decreasing the diffusional resistance of
skin.16  Enzyme activity present in the mouth may also contribute to the metabolism of
some drugs.55  As such, enzymatic inhibitors have been studied to prevent drug
degradation in the mouth.
Most penetration enhancers exert their effects by disrupting the membrane
integrity of the mucosa, thereby increasing membrane permeability and drug penetration
into mucosal tissues.51  However, tissue irritation at the site of application is a concern.
Because the oral mucosa is commonly exposed to mechanical and chemical irritants, it is
an ideal region to examine the efficacy and overall safety of penetration enhancers.46
Researchers are now investigating penetration enhancers that are reversible in action and
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are inert to the cells it comes in contact with.51  Recent investigations have looked at
several types and classes of penetration enhancers.  
Chitosan, a marine origin mucopolysaccharide, has not only demonstrated itself
to be an effective penetration enhancer, but is also nontoxic, biocompatible, and
biodegradable.51  Chitosan was investigated for its ability to deliver transforming growth
factor-β (TGF-β), a large, hydrophilic peptide molecule to which the oral mucosa was
reported to be relatively resistant to penetration.51  Results of this study showed a six to
seven-fold enhancement of mucosal permeability to TGF-β with the concurrent use of
chitosan.51  A possible mechanism for enhanced penetration of TGF-β can be attributed
to the bioadhesive nature of chitosan, which increases drug retention at the site of
application.51  Another scenario is based on chitosan’s ability to disrupt lipid micelles in
the intestine, thus attributing increased drug permeability to lipid disruption or
interference within the buccal epithelium.51, 55
Bile salt enhancers are the class of compounds most commonly used for drug
permeation enhancement.55  Bile salts have been utilized extensively to enhance drug
absorption through various types of epithelia including nasal, rectal, ocular, pulmonary,
and vaginal.55  Bile salts create aqueous channels via extraction of membrane protein or
lipids, increasing membrane fluidity, and reverse micellization in membrane.55  Many
bile salts also exhibit an inhibitory effect on membrane peptidases that are found within
the mucosa.55
In one study using dogs, the buccal administration of insulin coupled with the
bile salt enhancer, sodium glycocholate, resulted in a significant decrease in blood
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glucose, comparable to that seen after intravenous insulin injection.56  In a similar study,
non-diabetic beagle dogs received either insulin or insulin with sodium glycocholate.
Blood glucose decreased only with insulin and sodium glycocholate combination.57
In a subsequent study, the co-administration of the nonapeptide buserelin (a
luteinizing hormone-releasing hormone agonist), and sodium glycocholate was
examined in pigs.46  The mean bioavailability (F = 5.3%) was increased five-fold when
compared to buccal administration without the enhancer. 46  Higher steady state plasma
levels were also noted in the pigs treated with the combination.
The effect of sodium glycodeooxycholate on the transbuccal permeation of
morphine sulfate was studied using excised non-keratinized bovine buccal mucosa as a
model for human mucosa.55  It was demonstrated in vitro that the permeability of bovine
buccal mucosa was enhanced by a factor of 5, when 100 mM concentrations of the bile
salt were used.  No enhancement occurred when lower 10 mM concentrations of sodium
glycodeoxycholate were used.   Permeability studies were followed by histological and
infrared studies to further explain how the bile salt interacted with and modified the
drug. 55  Results of the studies indicate that sodium glycodeoxycholate interacts with the
lipids within the epithelia, decreasing diffusional resistance to the permeants. 55
Prodrugs
A practical consideration, but one that has been shown to affect the
bioavailability of buccally administered drugs, is taste.52  For example, many opioid
agonists and antagonists taste bitter—a feature that could negatively affect buccal
administration and subsequent absorption. 52  Hussain et al52 examined the possibility of
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delivering opioid agonists and antagonists in bitterless prodrug forms and the subsequent
effect these dosage forms had on bioavailability. When nalbuphine and naloxone were
administered to dogs via the buccal mucosa, the bitter taste of the drugs caused excess
salivation and swallowing.  As a result, the drug exhibited low bioavailability.
Administration of nalbuphine and naloxone in prodrug form caused no adverse effects,
with bioavailability ranging from 35 to 50%.  This is a marked improvement over the
oral bioavailability of these compounds, which is generally 5% or less. 52  It should be
noted, however, that the absorption of prodrugs must be more rapid than their
dissolution, in order to prevent the development of a bitter taste. 52
pH
In a recent study, Shojaei et al45 utilized porcine mucosa in order to determine the
major routes of buccal transport of acyclovir and to examine the effects of pH and
permeation enhancer on drug absorption. Buccal mucosa was excised from porcine tissue
(approximate area of 0.75 cm2) and mounted on side-by-side flow-through diffusion
cells bathed in isotonic buffer solution.  The permeability of acyclovir was evaluated at
pH ranges of 3.3 to 8.8, and in the presence of the absorption enhancer, sodium
glycocholate.  The in vitro permeability of acyclovir was found to be pH dependent with
an increase in flux and permeability coefficient at both pH extremes (pH 3.3 and 8.8), as
compared to the mid-range values (pH 4.1, 5.8, and 7.0).  In contrast, the permeation
enhancement was pH independent:  acyclovir absorption increased 2 to 9 times in the
presence of sodium glycocholate regardless of the pH.
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Buccal administration of fentanyl has been studied using a specially constructed
Teflon cell attached to the buccal mucosa of six dogs.  Streisand et al53  hypothesized
that the transmucosal bioavailability and absorption of fentanyl could be improved if
more of the drug was converted to its unionized form.  Because fentanyl is a basic drug,
the pH of the delivery vehicle could be increased, thus potentially converting more
fentanyl to the unionized form.  This was achieved using pH buffered fentanyl solutions
with pHs of 6.6, 7.2, and 7.7, respectively.  Arterial blood samples were collected at
frequent intervals over a period of eight hours.  Peak plasma concentration,
bioavailability, and permeability coefficient demonstrated a three-to five-fold increase as
the pH of the fentanyl solution increased.  In each case, regardless of pH, time to peak
plasma concentration occurred within ten minutes of removal of the fentanyl cells from
the buccal mucosa.  The mean Cmax for the pH 7.7 drug solution was nearly three times
that of the mean Cmax at pH 6.6.  Based on these results, higher fentanyl concentrations
could occur simply by altering the pH of the environment or by buffering the fentanyl
solution.56
Although this study was geared toward eventual clinical use and application in
human medicine, it does have relevance in veterinary clinical medicine.  Already, the
transdermal fentanyl patch is gaining broader popularity and acceptance in veterinary
medicine.  This method of fentanyl delivery has demonstrated its safety and efficacy in
both dogs and cats.  However, the patch must have adequate contact with the skin for a
variable, but sustained period of time.  The skin must be clipped and dried first, and
bandaging material should be applied to assist in patch placement and adhesion.  As is
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the case, and often the frustration of many veterinarians, animals sometimes are able to
remove bandaging material.  Should this occur, drug delivery and subsequent pain
alleviation are also terminated.  Also, if the animal ingests the removed patch, there is a
risk (though minimal) for toxicity.37  Thus, a dissolvable buccal patch that provides
sustained, therapeutic drug concentrations without the need for bandaging, skin prep,
and prolonged adhesion times would be advantageous.
Patch design
Several in vitro studies have been conducted regarding buccal patch bioadhesive
properties, the influence of application site, and drug release characteristics.  From these
studies, information was gathered on variables that affect drug absorption and delivery
via the buccal mucosa.  In one report, it was found that the type and amount of backing
materials altered the adhesion characteristics of buccal patches, and these changes could
alter the drug release profile.49  Also, the drug release pattern was different between
single-layered and multi-layered patches.49
Specific Drugs Delivered to Animals via a Buccal Patch
Several drugs and drug classes have been studied in an effort to determine the
feasibility of using buccal patches as a novel route of drug delivery.  These studies have
explored the consequences of altering patch design, pH, and including permeation
enhancers in the patch formulation The sheer variation in class of compounds illustrates
the interest the medical, veterinary, and pharmaceutic industries have on alternative,
more feasible routes of administration for existing drugs.
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Steroids
The oral and parenteral bioavailability of testosterone is rapidly absorbed and
metabolized by the liver.54  Due to this high first-pass effect, the half-life of testosterone
is very short. 54  As a result, the more lipophilic testosterone esters are used instead of
testosterone.  However, no current testosterone therapy results in sustained, therapeutic
drug levels.  Recent medical need for a sustained testosterone plasma level in human
males has generated interest in alternative forms of administration that will achieve this
goal.  Bioavailability of testosterone in the form of a bioadhesive tablet was determined
in a study conducted by Voorspels et al.54  Tablets containing 60 mg of testosterone were
affixed to the buccal mucosa of six dogs.   Testosterone was also administered orally and
intravenously, with bioavailability and additional pharmacokinetic parameters analyzed
for three formulations.  Oral administration of testosterone had a significantly lower
absolute bioavailability (1.03 % ± 0.75) when compared to buccal administration
(14.14% ± 0.75).54  In addition, only the bioadhesive tablet was able to sustain target
drug concentrations for 20 hours.54
A systemic amount of drug, however, is not always the desired effect of all
formulations.  The need for local activity to treat specific areas of inflammation or
infection is also of interest.  Local treatment is based on high concentrations of drug
being maintained at the site of administration, with minimal or absent systemic effects.
Hydrocortisone acetate is an anti-inflammatory agent contained in many topical products
intended for local application on the skin.  Previous studies have shown topical buccal
therapy of steroids is useful in treating local ulcerative and inflammatory mucosal
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conditions.58  A buccal mucoadhesive formulation of hydrocortisone was developed in
order to elicit a controlled amount of drug at the site of action, enhance bioavailability,
and ensure optimal contact with the absorbing surface.58
Antimicrobials
A bioadhesive tablet containing miconazole was used to examine the influence of
application site on bioadhesion and release characteristics.59  The study was undertaken
to determine if a novel method of drug therapy could reduce typical nosocomial
infections in intensive care patients.  The treatment of using a combination of antifungals
in paste form has not been shown to reduce these infections.11, 59  In this investigation, 10
mg miconazole nitrate tablets were attached to the buccal mucosa or gingiva of 8
comatose, intubated human patients.  It was concluded that the buccal mucosa was the
better application site for bioadhesive miconazole tablets.59  When applied to the
gingiva, salivary miconazole concentrations could only be observed 660 minutes post-
application.  In contrast, drug concentrations were detected much earlier and at a higher
concentration when attached to the buccal mucosa.
Peptides
Peptide delivery via a buccal patch has been examined in a number of
investigations.  In a randomized crossover study, Hoogstraate et al46 administered the
luteinizing hormone-releasing hormone antagonist, buserelin, intravenously and
buccally, with and without absorption enhancer, to six pigs. Buccal administration of the
drug resulted in rapid steady state plasma levels.  The mean bioavailability of buccal
delivery without enhancer was 1.0%.  With enhancer, mean absolute bioavailability
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increased to 5.3%.  This study not only indicates the potential for peptides to be buccally
delivered, but illustrates that therapy could theoretically be improved by altering the
composition of the delivery device, in this case, using an absorption enhancer.46
Further peptide delivery studies were undertaken by DeGrande et al42 to examine
the potential use of a TMDD system to deliver low molecular weight heparin to dogs. In
this study, three dogs received two patches placed on the right and left buccal mucosa
for 8 hours.  Each patch contained 13.4 mg of heparin.  Maximal plasma concentration
of heparin reached 0.8 units/ml at 6 hours, and declined slowly until patch removal at 8
hours.  Since the therapeutic drug concentration for heparin to prevent thromboembolism
is 0.1 to 2 U/ml, this study indicates the potential for the buccal patch to deliver
therapeutic drug doses in patients and provide adequate thromboembolic prophylaxis.42
In addition, this data suggests the possibility of delivering other peptide macromolecules
via the buccal route as an alternative to traditional parenteral administration.42
In an additional investigation,10 human insulin was administered buccally to
streptozocin-induced diabetic rats. Although the data did not suggest a significant
therapeutic benefit from using the buccal mucosa as a site for insulin delivery, the study
did demonstrate that a pharmacologic effect (decrease in blood glucose level) could be
achieved following buccal administration.10
Anesthetics and analgesics
Further clinical applications of buccally administered drugs focus on anesthesia
and analgesia. One of the challenges of anesthesia and analgesia is delivering the ideal
dose of drug to control an individual patient’s pain, or to maintain sedation without
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fluctuations into and out of consciousness.  Due to extensive inter-patient variability,
over- and underdosing often occurs with injections or oral administration of drugs.39, 60   
Thus, the development of a titratable drug formulation for a patient’s individual needs
would be of significant clinical interest.
  In one such study, 60 the sedative-hypnotic drug etomidate was administered
across the oral mucosa of dogs in a solid dose form. Though etomidate is used mainly for
the intravenous induction of general anesthesia, it was the investigators’ purpose to study
etomidate’s practical use as a premedication and sedative in conscious patients. For an
oral transmucosal system to deliver titratable amounts of drug, rapid onset must occur
when the drug is applied to the oral mucosa, as well as rapid termination upon removal
of the dose form.60  Both rapid onset and termination of etomidate occurred with buccal
mucosal absorption.  Canine buccal mucosa was also highly permeable to etomidate.
These results suggest the clinical use of buccally administered etomidate to achieve a
specific, tailored, and titratable dosing regimen for individual patient needs.60
DeGrande et al42 also investigated the use of buccal patches to deliver
buprenorphine to dogs in order to provide a more stable and sustained serum drug
concentration. Buprenorphine is a partial opiate agonist used clinically in the
management of acute and chronic pain.  Oral doses undergo significant first-pass
metabolism and rapid clearance, resulting in poor bioavailability in both dogs and
humans.4, 61, 62  Buccal patches (0.5 cm2) containing 1 to 4 mg of drug were applied to
four Beagle dogs in a crossover study.  Single patches of each dosage were applied for 8
hours to the lip or gingiva of the dogs.  Measurable drug concentrations were present
38
within 30 minutes after patch application, with Cmax occurring by 4 hours.  Although
there was notable inter-animal variability in both Cmax and AUC within treatment
groups, all dogs exhibited opiate related clinical signs (miosis, sedation, unsteady gait,
vomiting).
Drugs affecting the cardiovascular system
The angiotensin-converting enzyme inhibitors enalapril and linisopril have both
been studied as to their extent and precise mechanism of buccal absorption.63  Results
showed enalapril to be absorbed to a  slightly greater extent than is linisopril.  However,
it was noted that the extent of buccal absorption was much less than 60%--the
percentage of enalapril absorbed after oral administration.  Based on these results,
enalapril would probably not be absorbed to a large enough extent from the oral mucosa
to produce therapeutic drug levels, such as that needed for treatment of a hypertensive
crisis.63
In contrast, the buccal mucosa is a more than adequate site for the absorption of
other drugs that impact the cardiovascular system.  Its suitability to deliver clinically
effective amounts of drug was demonstrated in a study examining application of
transdermal nicotine patches to the buccal cavity of dogs in order to evaluate
cardiovascular effects.64  The study was conducted due to public safety concerns over
inappropriate use or exposure to transdermal nicotine patches (e.g. children biting or
chewing patches).  In fact, application of the patches to the oral cavity for a period of
only five minutes resulted in plasma nicotine levels greater than 1000 times that of
previously reported levels following either oral or transdermal routes in dogs.64
39
Cardiovascular effects were significant, with systolic arterial pressures rising as high as
400 mmHg within the five minute period of exposure.  Ventricular arrthymias and
tachycardia were also observed.  Investigators hypothesize that the cause of higher
nicotine levels was multifactorial.  The first-pass hepatic metabolism that would occur
with oral administration (e.g. swallowing) was avoided following buccal exposure.
Also, the composition of the transdermal patches seemed to be ideal for the rapid
delivery of significant amounts of nicotine via the buccal mucosa.64  The researchers did
note, however, the possibility that the proximity of the jugular vein sample site to the
capillary system of the buccal cavity may have attributed to the higher plasma levels of
nicotine.64  This study implicates the buccal surface as an alternate route of drug
administration that not only delivers detectable, pharmacologic levels of drug, but
quantitative clinical effects in arterial blood pressure and heart rate as well.
DRUGS TO BE INVESTIGATED IN THIS STUDY
This study will focus on the systemic delivery of butorphanol and albuterol via a
buccal patch.  The two drugs differ in their chemical composition, physical properties,
and their clinical use in medicine.  As such, results of this study will provide information
on the feasibility of delivering these drugs that have slightly different physiochemical
properties across the oral mucosa.
Albuterol
Albuterol sulfate is a synthetic, sympathomimetic β2-agonist that causes
relaxation of bronchial, uterine, and vascular smooth muscles.  It is one of several
adrenergic compounds developed for the treatment of asthma in humans.65  Albuterol is
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available in both oral and aerosol forms, although intravenous, intramuscular, and
subcutaneous methods of administration have been reported in the literature.65
Chemistry
Albuterol occurs as a white, crystalline powder.  It is soluble in water, slightly
soluble in alcohol, and has a molecular weight of 576.7.66   Albuterol’s β2-receptor
selectivity is achieved by modifying the basic catecholamine structure that is common to
the physiologic compounds epinephrine and norepinephrine (Fig 4).  For albuterol, this
modification consists of a tertiary butyl substitution on the nitrogen and the inclusion of
a hydroxymethyl group instead of the 3-hydroxyl group.65  Other β-agonists such as
terbutaline and fenoterol, can be produced with similar substitutions.  The result is a
compound that possesses specific β2 effects and negligible action on either α or β1
receptors.65
HO
HO
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NH CH3
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Figure 4—Chemical structure of albuterol.
Mechanism of Action
There are at least two types of β-adrenergic receptors: β1- and β2-receptors. β1-
receptors are primarily found in cardiac muscle and adipose tissue.67 When activated,
cardiovascular stimulation occurs. β2-receptors are predominately located in bronchial
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smooth muscle, the gastrointestinal tract, the blood vessels of skeletal muscle, and the
uterus.65, 66  β-adrenergic agonists exert their effects on these receptors by activating
adenyl cyclase, an enzyme present in the cell membrane.65  When activated, ATP is
converted to cyclic AMP.  Cyclic AMP then initiates a sequence of intracellular events,
eventually leading to a physiologic effect—in this case, inhibiting contraction of
bronchial smooth muscle, thereby causing smooth muscle relaxation and
bronchodilation.65, 67   In addition, bronchodilators decrease mucosal edema; are anti-
inflammatory; and stimulate airway mucosal secretion, resulting in a less-viscous
secretion and improved ciliary activity.68
Clinical Use
Albuterol is used in the management of asthma.  Asthma is a pathological lung
state characterized by bronchoconstriction and inflammation.68  In the treatment of
asthma, the most important therapeutic effect is the β2-receptor-mediated relaxation of
smooth muscle in the airways.65  β2-receptor agonists are the most effective
bronchodilators available because they block airway constriction, despite the inciting
cause.
Albuterol is widely used for the treatment of bronchial asthma in adults and
children.5, 69  However, in veterinary medicine, albuterol is infrequently used.  When the
drug is used, its primary indications are for the alleviation of bronchospasm or cough in
dogs and cats.  Albuterol reduced the cough in one-half of dogs with chronic
bronchitis.70  Routes of administration to small animals include aerosolization, oral
syrup, and tablets.68
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Recently, albuterol and other β2-agonists have been used in human medicine to
treat hyperkalemia caused by chronic or acute renal failure.71  Albuterol is effective in
lowering extracellular potassium by facilitating the intracellular uptake of potassium in
muscle and hepatic cells.71
Pharmacokinetics
Albuterol undergoes rapid and complete first-pass metabolism following oral
administration, resulting in reduced systemic bioavailability.68  The excretion and
bioavailability of albuterol is primarily affected by hepatic metabolism.5  Thus, if the
amount of drug presented to the liver was significantly decreased by using a novel
dosing method, with the reduction of subsequent hepatic metabolism, bioavailability
may be altered in comparison with conventional dosing forms.  Such modification in
pharmacokinetic parameters could offer several advantages including:  maintenance of
therapeutic drug concentrations, a less frequent dosing regimen, and improved
patient/client compliance.
The average oral bioavailability of albuterol administered in four different
preparations in dogs was determined in a study by Hernandez et al5 to be 80%.5
Elimination (disappearance) half-life was 1.2 hours after IV administration, 3.0 hours for
an oral immediate-release formulation, and ranged between 5.4 and 7.2 hours in an
orally administered sustained-release preparation.
Adverse Effects and Drug Interactions
Since β2-adrenergic receptors are present in sites other than the lungs, systemic
concentrations of albuterol can stimulate these receptors and cause a number of
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undesirable “extrapulmonary”effects.65  For instance, though normally the β1 effects of
albuterol are minimal, at increased doses, albuterol can stimulate these receptors,
resulting in tachycardia.65  Tachycardia may also be caused by the β2-mediated arteriolar
dilation, resulting in decreased peripheral vascular resistance.65
Albuterol also enhances skeletal muscle tremor, primarily in the extremities of
human patients.  The tremors are thought to be the result of β2-receptor-mediated
decreases in the recovery period following muscle fiber contraction.65
Other adverse effects of albuterol include dose-related metabolic alterations,
resulting in increased concentrations of plasma glucose, renin, insulin, lactate, and
ketone.65  Decreases in plasma potassium, phosphate, calcium, and magnesium
concentrations have also been reported. 65
Sympathomimetic amines used in conjunction with albuterol may increase the
risk of adverse cardiovascular effects. Ventricular arrthymias can occur—especially in
patients with preexisting cardiac disease—with the use of inhalation anesthetics such as
halothane, isoflurane, and methoxyflurane.  Digitalis glycosides may also increase the
risk of cardiac arrthymias.  The vascular effects of albuterol can be potentiated with the
use of tricyclic antidepressants or monoamine oxidase inhibitors.  In contrast, drugs such
as propranolol that are β-adrenergic blockers, can antagonize the effects of albuterol.
Toxicity and Overdose
Clinical signs consistent with systemic albuterol overdose include hypokalemia,
weakness, tachycardia, tachypnea, hypersalivation, hyperthermia, and delirium.71  In one
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published report, 71 a dog developed albuterol intoxication after it had punctured and
decompressed the metal albuterol inhaler of a family member.
In cases of known albuterol overdosage, potassium supplementation is
recommended.71  Propranolol should be administered if cardiac arrthymias are noted in
order to cause a β-adrenergic blockade.  ECG, serum potassium, and blood pressure
monitoring are also recommended.71
In humans, albuterol administered in the form of an inhalation aerosol spray has
shown effectiveness in the treatment of bronchospasm with reversible obstructive airway
disease in adults and children, providing bronchodilation for a duration of 3 to 8 hours.61,
62  As a result, the drug must be taken 3-4 times daily in order to provide therapeutic
relief for a sufficient period of time.61, 62
Clinical Relevance
In the study by Hernandez et al, 5 the elimination (disappearance) half-life of
intravenously administered albuterol (1.2 hours) indicates that approximately 90% of the
dose is eliminated in four hours. This fact illustrates the need to administer the drug three
to four times daily, and further indicates the need for the design of sustained-release
formulations.5  An alternate route of drug delivery that could provide convenience and
longer duration of activity—thereby reducing the number of doses that must be taken
daily—would be of interest to both clinicians and patients.
Although therapeutic albuterol concentrations in dogs and cats are not defined,
current-dosing recommendations for dogs is 0.05 mg/kg PO every 8 hours.61  A buccal
formulation could potentially provide sustained plasma concentrations, perhaps allowing
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decreased dosing intervals, and increasing the drug’s use in veterinary medicine by
eliminating the inconvenience of multiple oral dosing.
Butorphanol
Butorphanol tartrate is a synthetic opiate agonist-antagonist, commonly used in
small animal medicine for its analgesic, antitussive, and sedative effects.48, 72, 73
Butorphanol is available in both oral and injectable preparations.
Chemistry
Butorphanol tartrate is a lipophilic drug that occurs as a crystalline powder and is
somewhat soluble in water and is insoluble in alcohol.66   The molecular weight for
butorphanol is 477.55.72   Butorphanol is a morphine derivative with kappa receptor
agonist and mu receptor antagonist properties.73-75  Opioids have multiple receptors that
are widely distributed throughout the body.73  These receptors are not specific to opioids,
but rather have “preferences” to different exogenous and endogenous opioids.
The chemical structure of the opioid derivatives is the determining factor on the
drug’s “fit” and action at the receptor site.73  Butorphanol differs from morphine by
chemical substitutions at the C3, C6, C14, and C17 positions  (Fig 5) .76  There is also an
oxygen molecule lacking between positions C3 and C4.76  In addition, opioids exhibit a
great degree of stereo-specificity.  Thus, one optical isomer may be an agonist, but its
enantiomorph can be either inactive or an antagonist.  As a result, not only is the
chemical structure of opioids an important determinant on site of drug action, but their
arrangement in three-dimensional space is also crucial.73
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Figure 5—Chemical structure of butorphanol.
Mechanism of Action
Butorphanol, like other opioids, exerts its pharmacologic effects by the
interaction with the opioid receptors found in the body.37, 74  There are three major opioid
receptors (mu, kappa, and delta) in the body.  The sigma receptor may no longer be
considered as a separate class or receptor, though its current status remains unclear.
Sigma receptors do not appear to cause analgesic effects.74  The delta opioid receptor
appears to result in analgesia primarily at the level of the spinal cord.74
Most of the actions of morphine-like drugs seem to be mediated through the mu
opioid receptor.74  There are two subtypes of mu receptors that are responsible for
analgesia and sedation: mu1-receptors that act above the level of the spinal cord, and
mu2-receptors that act within the spinal cord.
37  Mu2-receptors are also thought to be
responsible for respiratory depression and suppression of gastrointestinal motility.74
The kappa opioid receptor is involved in spinal and supraspinal analgesia, miosis,
and sedation.74  Although both kappa and mu receptors mediate analgesia, mu agonists
cause euphoria, while kappa agonists produce sedation and dysphoria.74  Butorphanol is
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an opioid agonist-antagonist that exhibits agonist effects at kappa receptor sites, and
antagonist effects at mu receptors.
Clinical Use
Butorphanol is commonly used in veterinary medicine as a preanesthetic and
perioperative analgesic agent in cats and dogs.37, 74  It is also used as an antitussive, an
antiemetic prior to cisplatin treatment, and for the control of post-operative pain in small
animals.37  In horses, butorphanol is commonly used as an analgesic, and after xylazine,
is the next best drug at controlling visceral pain.74  Butorphanol can also be used to
partially reverse the sedative or respiratory depressant effects caused by oxymorphone, a
pure opioid agonist.37
Pharmacokinetics
In veterinary medicine, the pharmacokinetics of butorphanol have been reported
in dogs, cats, rabbits, goats, llamas, and horses.76-80  In dogs, several different routes of
administration, including subcutaneous, intramuscular, and epidural have been
studied.73, 77   No intravenous butorphanol studies have been conducted in dogs.
The subcutaneous and intramuscular routes of administration were found to be
bioequivalent, based on the lack of a statistically significant difference between AUC
values.77  For SC and IM, the mean serum elimination (disappearance) half-life was
102.6 ± 24 and 91.8 ± 14.4 min, respectively.77  Mean Cmax was 33.3 ± 16.9 ng/ml at
Tmax 28.65 ± 13 min following SC administration.  After IM administration, Cmax was
25.1 ± 6.7 at Tmax 42.2 ± 13 min.
77  Following epidural administration of butorphanol,
mean elimination (disappearance) half-life was 186 ± 60 min.73   Maximum
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concentration of butorphanol and time to obtain this concentration was 42.28 ± 7.46
ng/ml and 13.88 ± 7.62 min, respectively.73
Adverse Effects and Drug Interactions
The primary adverse effects caused by opioids are CNS depression, respiratory
depression, and to a lesser extent, cardiac depression.  In ruminants, opioids may cause
excitement.80  Respiratory depression is generally dose-related, and more likely to occur
with mu receptor activation than with kappa activation.78  As such, butorphanol has a
high safety profile. In dogs and cats, respiratory depression caused by butorphanol
displays a ceiling effect so that increasing the dose does not increase the respiratory
depression.78  Effects on the gastrointestinal system are also minimal.78
The administration of other CNS depressants such as tricyclic antidepressants
and the phenothiazines, may intensify or prolong the depressant effects of opioids.37
Some phenothiazines, however, can potentially reduce the concentration of opioid
required for analgesia, while others have the opposite effect.37
Toxicity and Overdose
Butorphanol is, in general, a very safe drug with a greater margin of safety than
morphine.73  As such, risk of acute overdose or toxicity with butorphanol is low.73
Toxicity studies have indicated the LD50 in dogs following oral administration to be
greater than 50 mg/kg.79, 80   Clinical signs of butorphanol intoxication include CNS
depression, cardiovascular changes, and respiratory depression.  In case of overdose,
treatment with intravenous naloxone should be initiated immediately.  Fluid and oxygen
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supplementation, mechanical ventilation, and the administration of vasopressor agents
may also be required.
Clinical Relevance
Butorphanol is completely absorbed following oral administration, but with a
high first-pass effect—only 16.67% of the administered dose reaches the systemic
circulation.61  Butorphanol is also absorbed completely following intramuscular
injection.61  The development of a buccal patch delivery system for butorphanol could be
useful due to the potential of a longer duration of effect compared with injectable
formulations, and without the significant first-pass effect of orally administered
butorphanol.
PHYSIOCHEMICAL COMPARISON
The physiochemical properties of the drug to be studied are perhaps the greatest
determinant of rate and extent of oral mucosal drug absorption.43  In general, molecules
larger than 100 Da have a more difficult time in penetrating the oral epithelium. 43  It is
probable in the case of hydrophilic drugs that the rate of absorption is directly related to
its molecular size. 43  Such a relationship has not yet been demonstrated across the oral
mucosa for lipophilic drugs. 43  Hydrophilic drugs also appear to be more effective in
partitioning into the oral epithelium and basal lamina. 43  The more hydrophilic layers of
the basal lamina can be a potential barrier in the transport of extremely lipophilic
drugs. 43
Results of this study will provide information on systemic oral delivery of
butorphanol, and the larger, more hydrophilic drug, albuterol.  Data will be analyzed in
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order to determine the feasibility of delivering these drugs with slightly different
physiochemical properties across the oral mucosa.
ViroTex Buccal Patch
The patch to be utilized in this experiment is manufactured by ViroTex
Corporationa.   The patch, less than 1.5 cm diameter, is designed for application inside of
the mouth on the buccal mucosa (Fig 6).
Figure 6—ViroTex buccal patch
The patch is comprised of the drug and an adhesive polymer in a matrix-type
configuration such that systemic delivery of drug will achieve therapeutic effect. When
in contact with the oral mucosa, the hydrophilic adhesive causes gradual dissolution of
the patch.  The design of the patch causes immediate adherence to the mucosa, and
immediate and rapid drug delivery.
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CHAPTER III
STUDY PURPOSE AND PROCEDURE
STUDY PURPOSE
The overall purpose of this study is to determine the feasibility of drug delivery
in dogs using a TMDD system.  Feasibility will be based on anticipated therapeutic
efficacy, which in turn will be based on likelihood of achieving targeted drug
concentrations; and convenience, which will be based on the operation of the delivery
system and animal tolerance to drug administration via this route.
OBJECTIVES
 Two drugs, albuterol and butorphanol, will be studied.  The bioavailability of
each drug when administered buccally will be compared to intravenous administration.
Bioavailability (F) is determined by the following equation:
F = AUC buccal * dose(IV)
AUC IV ∗ dose(buccal)
where F is the proportion of an administered dose that enters systemic circulation.81  By
definition, after intravenous administration, bioavailability is 100% (F = 1.0).  Drugs
administered via other routes may exhibit incomplete bioavailability (F = < 1.0), due to
hepatic, gastrointestinal, or other forms of metabolism. 81  Although bioavailability is not
a criterion of clinical effectiveness, it is a parameter that must be determined for any new
drug or drug product.81  Bioavailability, itself, only demonstrates the amount and rate of
drug appearing in systemic circulation.  Bioavailability can be used to assess the
bioequivalence of different pharmaceutical preparations, but it does not mean the
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different forms are bioequivalent. 81  Variations in bioavailability are primarily caused by
differences in the efficiency or rate of absorption—factors that originate either with the
patient or with the dosage form. 81, 82
Due to first-pass metabolism, the routes by which these drugs can be
administered are limited.  Multiple dosing is often necessary to provide sustained and
clinically effective plasma concentrations.  Fractious, excitable, or painful animals may
not tolerate excessive or repeated handling for the purpose of drug administration or re-
dosing.  If these drugs can be successfully administered, absorbed, and distributed via a
novel buccal patch system, transmucosal delivery of these drugs may be a potentially
rewarding alternative to traditional routes of administration.
The study will also provide information on whether therapeutic concentrations of
albuterol and butorphanol can be successfully delivered using a buccal patch system.
The therapeutic dose of butorphanol for somatic analgesia in dogs has been extrapolated
to be 9 ng/ml.73  Therapeutic concentrations of albuterol in dogs have not been
established in any of the literature.  Data will be analyzed to determine if buccal
administration of butorphanol is capable of achieving therapeutic drug concentrations.
MATERIALS AND METHODS
Subjects
Three hound dogs with a mean weight of 23 ± 1.73 kg were studied using a
randomized crossover design, with each dog receiving albuterol and butorphanol by
buccal and intravenous administration.  Prior to the study, an Animal Use Protocolb was
submitted to and approved by the University Laboratory Animal Care Committee
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(ULACC).  Guidelines of the ULACC regarding the humane care, treatment, and
utilization of animals for scientific purposes were followed.  Dogs were housed at the
Texas A&M University Small Animal Clinic.  Dogs were fed according to daily dietary
requirements; no special diet was required for this study.  All dogs were found to be
clinically normal as evidenced by an initial physical exam.  A complete blood count
performed prior to experimentation revealed no abnormalities that were clinically
significant (Appendix A).  All dogs were heartworm negative and on heartworm
preventative.  On the day of each study, another physical exam was conducted, and a
baseline heart rate, respiration rate, and body temperature were recorded.
Drug Administration
Dogs were fasted at least 12 hours before each study, with water available free-
choice throughout the fasting and sampling periods.  Prior to each 12-hour study, dogs
were fitted with an indwelling jugular catheterc, aseptically placed in either the left or
right external jugular vein.  A two-week washout period occurred between all drug
studies.
In both the buccal and IV studies for albuterol and butorphanol, vital signs such
as heart rate and respiration were monitored before drug administration and at various
time points following drug delivery.  In the event of an overdose or adverse reaction to
the drugs, reversal agents for albuterol and butorphanol—propranolol and naloxone,
respectively— were kept immediately on hand throughout the study period.  Any
negative effects or reactions were to be treated by one of the veterinarians involved in
the investigation and present on the day of the study.d  
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Buccal patch study
For the buccal patch trial, a ViroTex patch formulated to contain 0.9 mg of
albuterol was placed on the buccal mucosa of each dog and held in place for 10 seconds
to ensure adequate contact.  The patch was affixed to the mucosa of each animal in an
area approximately between the upper canine and molar teeth on the left side (Fig 7).
The mean buccal albuterol dose was 0.039 ± 0.003 mg/kg.
                               Figure 7—Application of buccal patch to oral mucosa.
Animals were closely observed for the first thirty minutes to ensure the patch was not
removed via excess salivation, licking, or other means of mechanical removal.  In
addition, water was withheld for the first thirty minutes to guard against interference
with patch dissolution or attachment.  Animals were also observed for adverse
reactions—either behavioral or physical—to the patches.
A ViroTex buccal patch containing 1.2 mg of butorphanol was attached to the
oral mucosa of each dog in the same manner described in the albuterol study.   Animals
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were again observed for proper patch attachment, placement, and dissolution.  The mean
buccal butorphanol dose was 0.05 ± 0.003 mg/kg.
IV study
For the IV portion of the study, albuterole (0.18 mg/ml) was slowly administered
into the cephalic vein via a Butterfly infusion set.f  Albuterol is a β-agonist and adverse
effects may include tachycardia, hypertension, CNS stimulation, vomiting, and
bronchodilation.  There are no intravenous dosing recommendations for albuterol in the
veterinary literature.  Albuterol is generally used as a nebulizer in veterinary medicine
with the recommended human dose as 200 µg.68   Heart rate and respiration were closely
monitored, and the β-blocker propranolol (0.25 mg/kg IV)g was immediately on hand
and available for administration in the event of overdose.  All dogs experienced
tachycardia and restless upon intravenous infusion.  As a result, the albuterol infusion
was discontinued when approximately half the 0.9 mg buccal patch dose of albuterol
was administered.  The mean IV albuterol dose was 0.018 ± 0.004 mg/kg.
A bolus dose of butorphanolh (0.5 mg/ml) was administered intravenously
according to the same procedure used in the albuterol infusion.  The total dose
administered IV was identical to the buccal patch dose of 1.2 mg, or 2.4 mls.  The mean
IV butorphanol dose administered was 0.05 ± 0.004 mg/kg.  Adverse effects of
butorphanol include sedation, anorexia, respiratory and cardiovascular depression, and in
rare cases, diarrhea.37, 61   Naloxonei (0.04 mg/kg IV)  can be used to treat overdose, and
was available during  intravenous administration.  The recommended IV dose of
butorphanol in dogs ranges from 0.1-0.4 mg/kg.  Based on a 23 kg dog such as those
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used in these studies, the lower-end dose is approximately 5 mls of 0.5 mg/ml
butorphanol IV.  Since the total dose of 1.2 mg (or 2.4 mls of 0.5 mg/ml butorphanol)
used in this study is approximately half of the low-end recommended dose for
butorphanol, adverse effects were not expected.
Sample Collection and Handling
Blood samples for the buccal patch studies for either drug were collected via the
jugular catheter at 0, 5, 10, 15, 30, 60, 90, 120, 150, 180, 240, 360, and 720 minutes.
For each sample, 0.25 ml of blood was withdrawn and discarded.  Another 7 ml of blood
was collected, and the catheter flushed with 7 ml of  0.9% saline.j  The 7 ml of blood was
immediately put into plain, red top tubesk and placed on ice until centrifugation.  Within
two hours after initial collection, the blood was centrifuged and the serum harvested.
Serum samples were stored in 1 ml aliquot tubesl at -90°C until analysis.
For the IV portion of the study, samples were collected via jugular catheter by
the same procedure as the buccal patch trial at 0, 2, 5, 10, 15, 20, 30, 45, 60, 75, 90, 120,
150, 180, 240, 360, 480, and 720 minutes.  Because the intravenous dose peaked
immediately, additional, early sampling times were included compared to the buccal
patch sample collection times.   Sample handling was identical to the buccal patch study,
with all blood centrifuged and serum harvested within two hours.
Sample Analysis and Validation
Prior to drug analysis, samples were thawed at room temperature.  Serum
concentrations of albuterol and butorphanol were determined by ELISA in accordance
with manufacturer’s guidelinesm and following validation in canine serum.  An
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individual standard curve was prepared for each compound in canine serum.  In addition,
individual stock solutionsn, e for each drug were prepared.  A serum stock solution for
each compound was prepared by combining a known volume of pooled blank canine
serum with its respective stock solution.  Individual standard points were then prepared
by spiking a known volume of blank serum with each compound’s serum stock solution.
All standard curves were accompanied by controls that spanned the width of the standard
curve.  All standard curves and controls were analyzed in duplicate with the mean value
serving as the point for the curve.  All serum samples collected at each time point were
also run in duplicate.  The lower limit of quantitation for the albuterol assay was 0.332
ng/ml and the upper limit was 8.53 ng/ml.  The upper and lower limits of quantitation for
butorphanol were 8.8 and 0.23 ng/ml, respectively (Appendix B).  Any serum samples
that were above the upper limit of quantitation were diluted appropriately and re-
analyzed (Appendix C).
PHARMACOKINETIC AND STATISTICAL ANALYSIS
Pharmacokinetic Calculations
For each drug and route, log plasma drug concentration verses time data were
subjected to computer-assisted linear regressiono to determine values for
pharmacokinetic parameters.  Noncompartmental analysis was implemented using either
an intravascular single bolus dose or extravascular dose model.  Values for parameters
were estimated using a linear/log trapezoidal rule, with lambda being estimated to
infinity.83, 84  Drug concentrations are reported as average values calculated from
duplicate samples that exhibited no more than 15 % difference. Area under the curve
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was determined to the last time point using the log-linear trapezoidal rule.  Peak plasma
concentration (Co) was extrapolated from the first non-computer-generated measurement
at the actual time, Tmax.  Bioavailability (F) was calculated according to the equation:
F = AUC buccal * dose(IV)
AUC IV ∗ dose(buccal)
Clearance was determined using the equation:
Cl = Dose IV/AUCIV
Volume of distribution at steady state was calculated using the equation:
Vss = Dose IV/AUMCIV/(AUCIV)
2
Mean absorption time (MAT) was calculated for the buccal patch formulations of both
drugs using the equation:
MAT = MRT (extravascular) – MRT (intravascular)
Means, harmonic means (for disappearance half-life), and standard deviations (pseudo-
standard deviation for disappearance half-life) were determined utilizing a statistical
software package.p
Statistical Methods
Selected pharmacokinetic parameters were compared between administration
routes (buccal v. IV) using a paired Student’s t-test to compare the first-order
elimination rate constant for buccal and IV dosing routes.  A value of p ≤  0.05 was
considered statistically significant.
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CHAPTER IV
RESULTS
Animals tolerated application of the buccal patch well.  No adverse effects
related to patch application were noted on gross exam of the oral mucosa following
dissolution of the patch.  Also, animals did not exhibit any clinical signs of toxicity or
overdose.  All patches dissolved within five minutes of application. Dissolution was
verified by examining the mucosa on which the patch was applied.
No adverse effects, behavioral changes, or tachycardia were noted after buccal
albuterol administration. Heart rate was monitored at periodic intervals throughout the
day of experimentation, and did not vary from baseline heart rates attained prior to drug
administration.  In contrast, all dogs experienced tachycardia following intravenous
administration of albuterol (Table 3).  The dogs also vocalized and exhibited behavior
indicating anxiety (e.g. pacing, panting).  Because administration of an intravenous dose
equivalent to the albuterol buccal patch (0.9mg) was determined by the investigators to
represent too great a risk of toxicity and potential overdose, the dogs received
approximately 0.45 mg, half of the 0.9 mg buccal albuterol dose. Despite the side
effects, administration of propranolol was not deemed necessary following IV
administration, as determined by the investigators.
Following intravenous administration of 1.2 mg of butorphanol, no dogs
exhibited adverse effects or signs of toxicity.  No opiate related clinical manifestations
(e.g. sedation, miosis) were exhibited in any of the dogs.
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Table 3—Heart rates after albuterol IV administration.
Time
(post-
injection)
Mean Heart
Rate
(beats/min)
SD
0
(baseline)
109 12.06
30 sec 136 38.57
1 min 180 20.00
1.5 min 201 2.31
2 min 204 4.00
3 min 203 23.44
5 min 174 22.54
15 min 171 32.08
30 min 135 8.08
60 min 141 4.62
90 min 131 4.62
PHARMACOKINETIC AND STATISTICAL RESULTS
The mean time-concentration curves ± standard deviation for albuterol and
butorphanol are depicted in Fig 8-9 and Tables 4-7.  All pharmacokinetic results are
reported as mean ± standard deviation.  Individual dog drug concentration verses time
curves and pharmacokinetic parameters are reported in Appendix D-K.
Statistical comparisons between the rate constant of elimination for buccal and
IV drug administration are reported in Appendix L.
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Fig 8—Average concentration ± standard deviation of albuterol.
Fig 9—Average concentration ± standard deviation of butorphanol.
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Albuterol
Following IV administration, the extrapolated concentration (Co) of albuterol was 57.74
+ 9.04 ng/ml, Cl was 4.73 ± 3.91 ml/min/kg, and Vss was 2.13 ± 1.30 L/kg.
Additionally,  t1/2 was 364.20 ± 115.20 min, and MRT was 240.19 ± 39.75 min (Table
4). Following buccal administration, a Cmax of 10.28 ± 2.77 ng/ml occurred at Tmax 130 ±
17.32 min (Table 5).  Disappearance half-life was 160.96 ± 24.19 min, MRT was 260.42
± 12.60 min, and MAT was 20.22 ± 48.80 min. Buccal bioavailability was calculated to
be 34.79 ± 13.77 %
Table 4—Values for pharmacokinetic parameters of albuterol following single dose IV
administration of 0.45 mg.
**indicates a significant difference (p ≤ 0.05)
Parameter  Dog B Dog C Dog R Average SD
Co (ng/ml)  48.01 59.34 65.88 57.74 9.04
AUC (min*ng/ml)  1872.7 4539.57 4391.81 3601.36 1498.89
Lambda Z (1/min)  0.0022 0.0012 0.0023 **0.0019 0.0006
t1/2 lambda z (min)  311.35 573.51 304.72 364.20 115.20
Cl (ml/min/kg)  9.24 2.26 2.68 4.73 3.91
AUMC (min*min*ng/ml)  401940.65 1298251.95 966023 888738.53 453125.98
MRT (min)  214.63 285.99 219.96 240.19 39.75
Vss (L/kg)  3.54 1.87 0.99 2.13 1.30
63
Table 5—Values for pharmacokinetic parameters of albuterol following single-dose
administration of 0.9 mg in a buccal patch.
**indicates a significant difference (p ≤ 0.05)
Parameter  Dog B Dog C Dog R Average SD
Cmax (ng/ml)  7.24 12.66 10.95 10.28 2.77
Tmax (min)  150 120 120 130 17.32
AUC (min*ng/ml)  1806.84 3213.44 2559.96 2526.75 703.89
Lambda Z (1/min)  0.0050 0.0037 0.0042 **0.0043 0.0007
t1/2 lambda z (min)  138.2 184.95 166.78 160.96 24.19
AUMC (min*min*ng/ml)  496668.75 809296.6 651559.3 652508.22 156316.09
MRT (min)  274.88 251.85 254.52 260.42 12.60
MAT (min)  60.25 -34.14 34.56 20.22 48.80
Bioavailability (F) % 48.24 35.39 20.73 34.79 13.77
Butorphanol
Mean + SD Co for butorphanol following IV administration was 8.24 ± 5.55
ng/ml (Table 6).  Mean Cl was 137.87 ± 19.55 ml/min/kg, t1/2  was 172.12 ± 94.95 min,
Vss was 27.58 ± 10.14 L/kg, and MRT was 112.17 ± 6.16 min.  Following buccal
administration, Cmax was  6.66 ± 1.65 ng/ml at Tmax 170 ± 17.32 min (Table 7).
Disappearance half-life and MRT were 259.15 ± 33.12 min and 278.96 ± 43.16 min,
respectively and MAT was 166.80 ± 37.00 min. Mean bioavailability of butorphanol
following buccal administration was 606.04 ± 164.09 %.
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Table 6—Values for pharmacokinetic parameters of butorphanol following single dose
IV administration of 1.2 mg.
Parameter  Dog B Dog C Dog R Average SD
Co (ng/ml)  4.46 5.64 14.61 8.24 5.55
AUC (min*ng/ml)  428.52 327.51 264.21 340.04 82.92
Lambda Z (1/min)  0.0066 0.0030 0.0025 0.0040 0.0022
t1/2 lambda z (min)  105.42 230.10 277.91 172.12 94.95
Cl (ml/min/kg)  123.87 129.53 160.21 137.87 19.55
AUMC (min*min*ng/ml)  49785.73 37741.59 27762.04 38429.79 11027.96
MRT (min)  116.18 115.24 105.08 112.17 6.16
Vss (L/kg)  17.72 27.04 37.97 27.58 10.14
Table 7—Values for pharmacokinetic parameters of butorphanol following single dose
administration of 1.2 mg in a buccal patch.
Parameter  Dog B Dog C Dog R Average SD
Cmax (ng/ml)  7.15 4.82 8 6.66 1.65
Tmax (min)  180 180 150 170 17.32
AUC (min*ng/ml)  2288.98 1605.31 1905.91 1933.40 342.66
Lambda Z (1/min)  0.0023 0.0028 0.0029 0.0027 0.0003
t1/2 lambda z (min)  302.65 248.46 235.43 259.15 33.12
AUMC (min*min*ng/ml)  704828.3 480963.76 437137.33 540976.46 143581.88
MRT (min)  307.92 299.61 229.36 278.96 43.16
MAT (min)  191.74 184.37 124.28 166.80 37.00
Bioavailability (F) %  534.16 490.16 793.8 606.04 164.09
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CHAPTER V
DISCUSSION
This study was designed as a pilot study to determine the pharmacokinetics,
including bioavailability, of albuterol and butorphanol when administered via a buccal
patch.  The pharmacokinetic characteristics of butorphanol and albuterol have not been
determined in dogs following buccal and apparently, IV, administration.  The basis of
future clinical studies and therapeutic effectiveness depends on the understanding and
correct interpretation of pharmacokinetic parameters.  The drugs selected for this study
have different clinical indications that would benefit from persistent drug levels.  They
also contrast in physiochemical properties and molecular size, with albuterol being
smaller and more hydrophilic, and butorphanol larger and lipophilic.  By examining the
behavior and disposition of different model drugs when administered via a buccal patch,
conclusions regarding the suitability of similar drugs for buccal delivery can more likely
be determined.  In subsequent investigations, decisions can be made on how to enhance
delivery for problematic drugs, prolong delivery of drugs with a short half-life, and alter
dosing regimes of drugs that require frequent administration.
This study demonstrated that application of the buccal patch can be relatively
effortless, and correct placement (and initiation of drug delivery) can be achieved in
seconds.  In contrast to parenteral drug administration or fentanyl patch application, no
equipment or animal prepping is necessary.
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Albuterol
Albuterol is a selective β2-agonist, available as oral tablets, a syrup, or an
aerosol.  In humans, orally administered albuterol undergoes significant first-pass
metabolism, reducing bioavailability to as low as 10%.  The half-life of oral albuterol is
approximately five hours, thus requiring three to four-times daily dosing to maintain
bronchodilation.  Buccal administration of albuterol in humans or dogs has not been
examined either for clinical effectiveness or pharmacokinetic evaluation.
The Cmax of buccal albuterol in dogs in this study was 10.28 ± 2.77 ng/ml,
occurring at Tmax 130 ± 17.32 min.  The disappearance half-life was 160.96 ± 24.19 min.
The estimation of half-life for the buccal dose suggests approximately 90% of the drug
will be eliminated in 10-14 hours (around 4-5 half-lives).  This indicates the potential of
the buccal patch to allow twice daily dosing if therapeutic drug concentrations can be
maintained during this time period, an ability shared by controlled release albuterol
tablets currently on the market.  Compared to IV administration, the disappearance half-
life for buccally administered albuterol was nearly two-times greater than the elimination
(disappearance) half-life reported for the IV preparation by Hernandez et al5 (Table 8).
Albuterol has also been studied using oral preparations intended to prolong drug
concentrations, and some comparisons can be made to the buccal patch (Table 8).  The
formulations of albuterol used in the study by Hernandez et al5 are not available in the
United States.  As such, differences in pharmacokinetic parameters should not be over-
interpreted.  It does appear, however, that buccal albuterol could provide effective and
comparable plasma concentrations.  After 0.9 mg of buccal albuterol was administered,
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disappearance half-life values were comparable to the oral immediate release product
given at a dose nearly 10-fold the buccal dose.
Intravenous administration of albuterol to dogs in this study resulted in a longer
disappearance half-life than either buccal, oral, or the IV Ventolin preparation (Table
8).  Intravenous disappearance half-life should not be longer than extravascular
administration.  Possible situations that may have caused this effect include a terminal
portion of the curve that is poorly defined, and thus few points used to determine  the t1/2
Lambda Z.  In dog C, for instance, only three points were used in the t1/2 Lambda Z
calculation.  Dog C also had the longest t1/2 Lambda Z (573.51 min).  The terminal
curves of dogs B and R included twice as many points to calculate t1/2 Lambda Z, but the
calculated values (311.35 and 304. 72 min, respectively) were also longer than
extravascular disappearance half-life data.  The small study population used in this
investigation prevented outliers from being identified.  It would have been beneficial to
study the pharmacokinetic behavior of IV albuterol in a greater number of dogs to
determine if the results obtained in this investigation were valid .  In comparison to the
Hernandez et al study,5 in which a comparable IV albuterol dose was administered to
dogs similar in size to the dogs used in this study, it would appear that our results do not
correlate with the elimination (disappearance) half-life values obtained in their
investigation (Table 8).
When the elimination of the drug is more rapid than absorption, absorption
becomes the rate-limiting step, and a flip-flop model results.85, 86  Flip-flop models
sometimes occur following topical or rectal routes of administration, and metabolite
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concentration-time curves, if the metabolite is eliminated quicker than it is formed.85
As such, the absorption half-life following extravascular dosing is mistakenly thought to
represent the elimination slope of the curve.  It must be recognized, however, that in flip-
flop models the plasma concentration-time curve tends to parallel the rate of
absorption.87  To determine if a flip-flop model exists, comparisons should be made
between the elimination phase of the intravenous plot and the extravascular
concentration-time curve.  The elimination rate constants between intravenous and
buccal administration were compared using a paired Student’s t-test with a p-value less
than or equal to 0.05 considered significant.  Significant differences between the mean
elimination rate constants were detected for albuterol.  Although the elimination rate
does differ between the two routes, a flip-flop model does not exist for buccal albuterol
since the disappearance half-life for IV albuterol is longer than the buccal disappearance
half-life.  Additionally the IV route of administration has no absorption phase.
In the study by Hernandez,5 the elimination (disappearance) half-life of IV
albuterol was 72 ± 21.6 min; much shorter than the disappearance half-life of 396.53 ±
153.31 min in this study.  The previous investigation5 detected albuterol by high
performance liquid chromatography (HPLC) with a lower LOQ of 0.5 ng/ml, as
compared to the lower LOQ of 0.32 ng/ml in this study.  Additionally, the albuterol was
only detectable for a period of approximately 6 hours, in contrast to the twelve hours in
which albuterol was measurable in our study.  This suggests the longer disappearance
half-life obtained in our study could be because the lower LOQ of 0.32 ng/ml was able
to detect albuterol at a smaller concentration and for approximately double the time
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period in the previous investigation.   Similarly, in the transdermal albuterol study by
Gokhale et al,88 the lower LOQ was only 2 ng/ml and detectable concentrations of drug
were measured for less than eight hours.  If the LOQ used in this study was able to detect
a smaller quantity of drug, and thus identify a terminal component that was not evident
in previous studies, the disappearance half-life could be longer if the slope of this new
terminal component was not as steep as previous investigators.  However, this terminal
component may not reflect concentrations that are therapeutic.
Table 8—Values for pharmacokinetic parameters after buccal, IV, and oral albuterol
administration in dogs 5
NR = not reported
Buccal IV IV5
(Ventolin)
Oral5
(immediate
release)
Oral5
(sustained
release)
Dose (mg/kg) 0.04 0.02 0.02 0.39 .39
Total mean
dose (mg)
0.9 0.45 0.5 9.6 9.6
Cmax/Co
(ng/ml)
10.28 ± 2.77 57.74 ± 9.04 NR NR NR
Tmax
(min)
130 ± 17.32 NR NR
t1/2
(min)
160.96 ± 24.19 364.20 ±
115.20
72 ± 21.6 180 ± 46.8 324 ± 79.2
Vss
(L/kg)
NR 2.13 ± 1.30 NR NR NR
Cl
(ml/min/kg)
NR 4.73 ± 3.91 NR NR NR
MRT
(min)
260.42 ± 42 240.19 ± 39.75 66 ± 30 300 ±  102 702 ±  216
F (%) 34.79 ± 13.77 85 ± 12 82 ± 37
The bioavailability regarding albuterol administered via a buccal patch,
comparisons or extrapolations among species and studies should not be over-interpreted.
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Bioavailability studies have been conducted using immediate-and sustained-release oral
tablets.5  Mean bioavailability of these products was approximately 80%, more than
twice the 35% value calculated in this study (Table 8).  However, the study by
Hernandez et al5  did not report AUC data, thus AUC comparisons could not be made
among formulations.
Many factors can influence the bioavailability of orally administered drugs,
including:  gastrointestinal motility; the presence or absence of food or other drugs; age;
weight; disease state;  formulation of the drug; route of administration; and the
physiology of the patient.82, 88, 89  Food, antacids, and milk all delay gastric emptying,
and along with gastric acid, can directly interfere with the drug itself.82  The buccal route
of administration avoids first-pass effect, while oral drug formulations do not.  Thus,
buccally administered drugs should demonstrate greater bioavailability as compared to
drugs administered orally.  Unless the patch was swallowed, no drug should be presented
to the stomach.  All dogs in this study were fasted prior to drug administration, so even if
drug did reach the stomach, gastric motility and food would not impact bioavailability.
Albuterol has been studied following transdermal administration in an
investigation by Gokhale et al.88  The bioavailability of transdermally administered
albuterol in rhesus monkeys was 20%. The fact that the buccal formulation resulted in
greater bioavailability than the transdermal patch, indicates the potential of the oral
mucosa as being a suitable site for drug administration, and perhaps a more effective
route of delivery than transdermal patches.
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The type of drug formulation and physiochemical properties of the drug itself
will impact drug movement when administered as a patch.  Albuterol sulfate has a
molecular weight of 576.7, slightly larger than the 500 Dalton rule of drug absorption
proposed by Bos and Meinardi.32  Albuterol also is a hydrophilic drug, potentially
limiting its absorption and passage through the lipophilic regions of the oral mucosa.
This can be expected to decrease bioavailability as compared to oral preparations (Table
8).  The skin is characterized by an additional lipid barrier, the stratum corneum.  The
presence of this layer probably contributed to the lower bioavailability seen in the
transdermal study of albuterol,88 by lessening drug passage into the epidermal and
subcutis layers.
The Vss of albuterol was 2.13 ± 1.30 L/kg (Table 4, 8).  Depending on the
intended site of action, drugs that exhibit a small Vss may require a lower dose to
achieve clinical effect.  The Vss of albuterol is greater than the total body water (0.6 L),
suggesting it is distributed to areas other than the circulatory system. Drugs with large
Vss distribute to tissues including extracellular and intracellular fluid, fat, and deep
tissue, rather than being limited to the circulatory system.75, 90  The larger the apparent
volume of distribution, the smaller the concentration in plasma from a given dose,
because less drug is sequestered in the plasma.  Conversely, a small Vss suggests the
drug remains in the plasma or serum, and will result in higher drug concentrations.  The
Vss of IV albuterol was not reported in the investigation by Hernandez et al5, thus
comparisons between IV routes cannot be made.
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The pharmacokinetics of buccal albuterol have not previously been determined in
dogs.  Albuterol is used so infrequently in clinical veterinary medicine that therapeutic
concentrations have not been established.  Based on the lack of clinical response upon
buccal albuterol administration, it is unlikely that therapeutic levels were reached in this
study.  In addition, the total dose of albuterol administered buccally was less than the
recommended 0.05 mg/kg oral dose in dogs.61  Future considerations may include
altering the patch to contain more drug or including penetration enhancers in the patch
formulation.
Butorphanol
Butorphanol is completely absorbed after oral administration, but because of
extensive first-pass metabolism, oral bioavailability is low, necessitating increased
dosage frequency.  Butorphanol is also absorbed immediately following IM and SC
administration, with peak serum concentrations occurring one hour after parenteral
dosing.76  In order to avoid first-pass metabolism, along with the negative association of
injections, alternate, non-parenteral routes of drug administration have been developed.
The pharmacokinetics of butorphanol administered intravenously or via a buccal patch
have not previously been reported for dogs.
Following buccal administration, the disappearance half-life of butorphanol was
259.15 ± 33.12 min.  This was a longer disappearance half-life than previous reports
following IM, SC, or epidural dosing in dogs (Table 9), and after SC administration to
rabbits (98.4 ± 5.4 min).78  Thus, butorphanol given at therapeutic doses via a buccal
patch may have a longer duration of effect than after parenteral or oral administration to
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dogs, and parenteral administration to rabbits.  The disappearance half-life of 1.2 mg of
buccally administered butorphanol was longer than the elimination (disappearance) half-
life of a buccal patch containing 2 mg of butorphanol (195 ± 72.6 min) and applied to
the oral mucosa of human subjects.91
Butorphanol was absorbed slowly following buccal administration with a Cmax of
6.66 ± 1.65 ng/ml occurring at Tmax 170 ± 17.32 min.  The 2-mg buccal butorphanol
patch used by Shyu et al91  in healthy human volunteers resulted in lower Cmax and AUC
values, 0.78 ng/ml and 315.6 min*ng/ml, respectively, as compared to the Cmax and AUC
values in this study (6.66 ± 1.65 ng/ml and 1933 ± 342.66 min*ng/ml, respectively).
The 2-mg buccal patch achieved a Tmax of 204 min, a longer time period than the Tmax
attained in this study.  Normalizing dose for a 70-kg individual, the total butorphanol
dose administered in the human study was approximately 0.03 mg/kg, compared to the
0.05 mg/kg dose in this investigation.  Though slightly more drug was administered on a
mg/kg basis in this study, it is unlikely that such small differences can account for the
large disparity seen in the Cmax, AUC, and Tmax values between the two investigations.
These comparisons would indicate that the ViroTex patch is capable of achieving higher
plasma drug concentrations in a shorter duration of time.
Compared to the study conducted by Troncy et al73  and Pfeffer et al77, in which
IM, SC, and epidural injections of 0.25 mg/kg butorphanol were administered to dogs,
buccal butorphanol at 0.052 mg/kg was characterized by decreased Cmax concentrations
and later Tmax values (Table 9).   This indicates a slower and prolonged absorption of
buccal butorphanol as compared to IM, SC, or epidural administration.  However, the
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plasma disappearance of buccal butorphanol remained slower than that of parenteral
butorphanol, as demonstrated by the longer disappearance half-life achieved using the
buccal formulation compared to previous investigators (Table 9).  Although statistical
comparisons can not be made among these studies, the magnitude of the differences
among this disappearance half-life and other investigator’s suggests the difference was
real.
Table 9—Values for pharmacokinetic parameters after buccal, IV, SC77, IM77, and
epidural73 butorphanol administration in dogs.
NA = Not applicable
Buccal IV SC77 IM77 Epidural73
Dose (mg/kg) 0.052 0.052 0.25 0.25 0.25
Total mean
dose (mg)
1.2 1.2 2.75 2.75 6
Cmax/Co
(ng/ml)
6.66 ±  1.65 8.24 ± 5.55 33.3 ± 16.9 25.1 ± 6.7 42.28 ± 7.46
Tmax (min) 170 ± 17.32 1.67 ± 2.89 28.65 ± 13 42.2 ± 13 13.88 ± 7.62
AUC
(min*ng/ml)
1933.4 ±
342.66
340.04 ± 82.92 4902 ± 2058 4062 ± 972 7866 ±  2484
t1/2 (min) 262.18 ± 35.65 204.48 ± 89.05 102.6 ± 24 91.8 ± 14.4 186 ± 60
Vss (L/kg) NA 27.58 ±10.14 NA NA NA
Cl
(ml/min/kg)
NA 137.87 ± 19.55 NA NA NA
The AUC of buccal butorphanol was lower than the AUC of IM, SC, or epidural
administration (Table 9).  However, the total dose of buccal butorphanol was less than
either the IM, SC, or epidural doses (Table 9).  Extrapolating from this data, it would be
expected that if buccal butorphanol were to be given at doses comparable to the IM and
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SC dose (approximately twice the buccal dose) and epidural dose (5-times more than the
buccal dose), the AUCs of all formulations should be comparable.
Absolute bioavailability for buccal butorphanol was calculated as 606.04 ±
164.09%.  Bioavailabilities approximating 100% indicate complete absorption of the
drug.  However, bioavailabilities calculated by this study are physiologically unlikely,
indicating several potential problems or scenarios.  These include:  analytical
difficulties; trouble with patch design; physiologic interference; and drug metabolite
interference.
Serum samples following buccal and intravenous drug administration were
analyzed in duplicate and analysis was performed on two separate occasions with similar
results and coefficients of variability were within acceptable limits.  Thus, it is unlikely
that analytical mistakes caused variation in drug concentrations such that would alter the
AUC and cause the high bioavailabilities seen in this study.  Alternatively, more drug
may have been placed in the patch than cited.  Because extra patches were not made
available to our laboratory for analysis, the actual drug content of the patches could not
be verified.  Similarly, it is possible an incorrect or miscalculated intravenous dose of
butorphanol was administered.  Indeed, based on values of the IV pharmacokinetic
parameters determined in this study as compared to those of other investigations, 1.2 mg
of butorphanol IV should result in higher Co and AUC values.  For example, an IV dose
of approximately 2 mg administered to rabbits78 resulted in a Co of 106.40 ± 19.36
ng/ml.  Similarly, a 10 mg dose to llamas92 resulted in a Co of 94.8 ± 53.1 ng/ml.
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Unfortunately, no study has reported Co for butorphanol in dogs following IV
administration.
Possible physiologic explanations include enterohepatic re-circulation, in which
drugs appearing in the bile are emptied into the small intestine and are reabsorbed from
the intestinal lumen into systemic circulation.  Thus resulting in drug concentrations to
appear higher than they actually are.  However, analytical methods are not selective and
this phenomenon should occur for both buccal and intravenous butorphanol.   Other
physiologic scenarios include liver damage, causing increased plasma drug
concentrations of butorphanol, which is extensively metabolized by the liver.  As such, a
longer disappearance half-life and greater AUC would occur, resulting in an increased
bioavailability.
Cross-reactivity between butorphanol and its metabolites could also cause altered
values for pharmacokinetic parameters.  Metabolite cross-reactivity has not been defined
for the butorphanol ELISA assay,93 but if interference does exist, plasma concentrations
may be higher due to the presence of metabolites plus active drug.  In addition to
unknown metabolites, butorphanol has two recognized metabolites, hydroxybutorphanol
and norbutorphanol.93  Cross-reactivity to the unknown metabolites exists when
butorphanol is analyzed using radioimmunoassay. 79  When the half-life of the drug is
longer than that of the metabolite, the metabolite declines in parallel with the drug.94
Conversely, metabolite levels build up in the body only when the half-life of the
metabolite is longer than that of the drug. 93    Thus, by the time the peak metabolite level
is reached, most of the drug has been eliminated.  If cross-reactivity in the ELISA assay
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is present, metabolite—as opposed to actual drug concentration—may be what is
quantitated.  Bioavailability, area under the curve, and disappearance half-life would all
be increased.  However, as with enterohepatic re-circulation, metabolite measurement
should occur with both buccal and intravenously administered butorphanol, not just one
or the other.  Thus, cross-reactivity may well exist with ELISA analysis, but it would
cause increased reported concentrations for both buccal and parenteral dosing.  To define
whether cross-reactivity exists, HPLC may be performed.  High performance liquid
chromatography was used to quantitate butorphanol metabolites in goats, but no
evidence of metabolite formation was detected. 93
The pharmacokinetics of intravenous butorphanol in dogs have not previously
been determined.  However, there is marked variability in Vss among different species.
In this study, the Vss for IV butorphanol was 27.58 ± 10.14 L/kg and is larger than the
Vss in llamas (0.822 L/kg),92 rabbits (10.76 L/kg),78 cows (4.178 L/kg),95 and humans
(8.3 L/kg).96  Because the total body water of a 20 kg dog is approximately 12 L (60% of
total body weight, or 0.6 L/kg).  The Vss of IV butorphanol exceeds this value.  This
indicates rapid permeation of butorphanol and storage in tissues such as fat, located in
peripheral compartments.90, 97  The larger Vss indicates that increased doses are needed
to achieve therapeutic plasma butorphanol concentrations in dogs, compared to that
needed in other species.  However, as with Cmax, the difference also may reflect a dosing
error.
The minimum therapeutic plasma analgesic concentration of butorphanol in dogs
has been extrapolated to be 9 ng/ml.73, 93  Current dosing recommendations for IV, SC,
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and IM butorphanol at analgesic levels in dogs ranges from 0.1-1.2 mg/kg. 61  Dogs in
this study received approximately half of the lower-end recommended dose, or 0.05 mg.
A Co of 8.24 ± 5.55 ng/ml was reached following IV dosing and a Cmax of 6.66 ± 1.65
ng/ml after buccal administration.  Both concentrations are slightly lower than the target
plasma analgesic concentration of 9 ng/ml.  Thus, therapeutic drug concentrations for
analgesia were not reached using a butorphanol buccal patch containing 1.2 mg of drug.
Although antitussive concentrations for butorphanol have not been determined, doses
range from 0.05-0.11 mg/kg SC, similar to the dose administered in this study.
Therefore, 0.05 mg/kg of buccal butorphanol could potentially be effective as an
alternative route to provide antitussive activity in dogs.
Study Limitations
The purpose of this study was to provide a starting point for further
pharmacokinetic studies utilizing buccal patches.  Limitations of the information
gathered here include a small sample size of three dogs, from which it is difficult to
define outliers and arbitrary deviations in pharmacokinetic parameters.  To increase the
strength of interpretation, the sample size should be increased.  However, the number of
buccal patches made available by ViroTex Corporation restricted us from including
more animals.  Some patches were rendered unusable by mistakes made in adherence to
the oral mucosa, while other patches were swallowed and data could not be analyzed.
Further compounding data interpretation, was reluctance in divulging
“proprietary information” regarding patch composition.  For instance, the manufacturing
technique, type of vehicle used, whether the patch was unidirectional or bidirectional,
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and the presence or absence of penetration enhancers was unknown us.  As such,
interpretation of potential problems in patch design was forced to be more speculation
and conjecture than based on disclosed facts.  Thus, although useful preliminary
information was gained by the buccal patch study, more information is needed to
appropriately characterize the pharmacokinetic parameters of buccally administered
albuterol and butorphanol in dogs. In 1998, ViroTex Corporation was acquired by
another company.
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CHAPTER VI
CONCLUSIONS
Several useful conclusions can be made from this study.  Not only was the
disposition of albuterol and of butorphanol further characterized in dogs, important
information was gathered regarding values for the pharmacokinetic parameters of these
drugs when administered via a buccal patch.  There are no reported studies that have
examined the disposition of buccally administered albuterol or butorphanol, nor have the
values for the pharmacokinetic parameters of IV butorphanol been described for dogs.
At present, there are no buccal patch formulations that are available for use in
veterinary medicine.  Indeed, novel drug delivery systems such as iontophoresis and
phonophoresis are used only sparingly in the vast majority of veterinary clinics.  The
exception to this is the transdermal fentanyl patch for use as an analgesic.  Although the
fentanyl patch has demonstrated that therapeutic concentrations of drug can be achieved,
it is currently the only drug available in patch formulation.  Clearly, more studies need to
be conducted to further explore the benefits, advantages, and convenience that novel
drug delivery systems can afford the clinician both practically and economically.
Although this project was designed as a pilot study to define values for the
pharmacokinetic parameters of buccally administered albuterol and butorphanol,
important conclusions can be drawn regarding the drug delivery system itself.  Primarily,
the suitability of the oral mucosa to achieve systemic and sustained drug concentrations
was clearly illustrated by this study.  Higher drug concentrations of albuterol were
achieved with the buccal patch than with transdermally delivered albuterol.89
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Additional issues regarding buccal patch systems that were determined by this
study include: ease of patch application, rapid dissolution of the patch, convenience of
administration, and the fact that the patch was well tolerated by the dogs.  The
effectiveness of the buccal patch to deliver therapeutic drug concentrations is an area
that must be explored in future studies.  Analgesic concentrations of butorphanol were
not achieved in this study.  However, recommended parenteral antitussive doses of
butorphanol are lower than analgesic doses, and are equivalent to the dose provided by
the buccal patch used in this study (0.05 mg/kg SC).61  As such, it is certainly feasible
that this formulation could provide the necessary drug levels to attenuate and effectively
control coughing.  However, clinical studies are compulsory in order to ascertain this
fact.
The most significant conclusion of this study is the fact that novel delivery
systems are effective and convenient alternatives for traditional modes of drug
administration.  Although pharmaceutical companies believe oral dosage forms will
likely remain the primary drug formulation, the importance and recognition of
alternative routes of drug administration are likely to increase.98  In fact, it is estimated
that the annual sales for needle-free, alternative delivery systems will increase from $400
million to $1 billion by the year 2005. 98
Despite these positive industrial projections, more studies are indicated in order
to perfect, and possibly customize novel drug delivery systems for use in specific
veterinary species.  It is obvious from this study that although measurable drug
concentrations are achieved in the blood, there is a great deal of inter-animal variation
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and unpredictability that must be addressed before clinical use. Regardless, novel
delivery systems such as buccal patches offer many advantages over traditional routes of
drug administration.  Although more work must be performed in order to accurately
define pharmacokinetic and pharmacodynamic parameters in animals, buccal patches
have the potential to become an important delivery system for clinical use in the future.
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ENDNOTES
                                                           
a ViroTex Corporation; The Woodlands, Texas
b AUP # 7-272 approved 10/17/97 (phase II approved 9/9/98); AUP # 8-199 approved
August 25, 1998
c Venocath-18; Radiopaque IV Catheter; Abbott Park, Illinois
d  Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP;  Albert Boeckh, DVM,
Veterinary Clinical Associate; Sarah Jones, DVM, Veterinary Clinical Associate
e Albuterol; Sigma-Aldrich; St. Louis, Missouri
f E-Z Set Infusion Set; Becton Dickinson; Sandy, Utah
g Inderal; Wyeth-Ayerst Laboratories; St. Davids, Pennsylvania
h Torbutrol; Fort Dodge Animal Health; Overland Park, Kansas
i P/M Naloxone HCl Injection; Schering Plough; Kenilworth, New Jersey
j Physiological Saline Solution 1000 ml; The Butler Company; Dublin, Ohio
k Monoject; Sherood Medical; St. Louis, Missouri
l USA Scientific, Inc.; Ocala, Florida
m Neogen Corporation; Lexington, Kentucky
n Butorphanol tartrate salt 100 mg; Sigma-Aldrich; St. Louis, Missouri
o Pharsight Corporation; Mountain View, California
p Microsoft Corporation; Redmond, Washington
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APPENDIX A
Pre-Study Complete Blood Cell Count Results
November 1997
Test Normal Range
Dog
B
Dog
C
Dog
R
White Cell Count 6-17 x 103 /µl 7.6 7.6 7.1
Red Cell Count 5.5-8.5 x 103 /µl 5.8 5.9 5.34L
Hemoglobin 12-18 g/dl 13.6 14.1 12.0
Packed Cell
Volume 37-55% 39.8 40.4 34.6
L
Platelet Estimate 0.2-0.5 x 103 /µl NR NR NR
Segmented
Neutrophil Count 3-11.5 x 10
3 /µl 4.778 4.560 5.112
Band Neutrophil
Count 0-0.3 x 10
3 /µl 0.988H 0 0
Lymphocyte
Count 1-4.8 x 10
3 /µl 1.216 1.9 1.9
Monocyte Count 0.15-1.35 x 10
3
/µl 0.456 0.456 0.400
Eosinophil Count 0.1-1.25 x 103 /µl 0.76 0.532 0.284
Basophil Count Rare 0 76H 0
H Indicates high value (as compared to normal)
L Indicates low value (as compared to normal)
NR = not reported
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APPENDIX B
STANDARD CURVE QUALITY CONTROL
Controls used for albuterol assay
Conc.
(ng/ml) 8.530 5.600 3.790 2.520 1.123 0.332
Analysis #1
(ng/ml) 9.900 5.190 3.740 2.39 1.29 0.48
Analysis #2
(ng/ml) 10.450 4.670 4.540 2.440 1.290 0.240
       
N 2 2 2 2 2 2
Mean conc.
(ng/ml) 10.175 4.930 4.140 2.415 1.290 0.360
Std Dev 0.389 0.368 0.566 0.035 0.000 0.170
Prec Err 3.8 7.5 13.7 1.5 0.0 47.1
% Acc 119.3 88.0 109.2 95.8 114.9 108.4
Controls used for butorphanol assay
Conc.
(ng/ml) 8.800 5.930 3.950 *2.630 0.230
Analysis #1
(ng/ml) 7.880 5.120 4.300 1.8 0.29
Analysis #2
(ng/ ml) 8.100 5.120 3.870 2.060 0.200
      
n 2 2 2 2 2
Mean conc.
(ng/ml) 7.990 5.120 4.085 1.930 0.245
Std Dev 0.156 0.000 0.304 0.184 0.064
Prec Err 1.9 0.0 7.4 9.5 26.0
% Acc 90.8 86.3 103.4 73.4 106.5
* Shaded area indicates a control point not used.
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APPENDIX C
Intravenous albuterol assay dilutions
♦ Methodology used
Dog Time Dilution
Factor Actual Conc.
Concentration
B 2 10x 3.412 34.12
B 5 5x 4.088 20.44
B 10 5x 3.34 16.67
B 15 2x 5.145 10.29
C 2 10x 4.5 45.06
C 5 5x 5.96 29.82
C 10 5x 4.22 21.12
C 15 5x 3.96 19.88
C 20 5x 3.31 16.53
C 30 5x 3.34 16.87
C 45 5x 3.64 18.2
C 60 2x 4.78 9.56
R 2 10x 5.79 57.9
R 5 10x 4.77 47.7
R 10 10x 3.59 35.92
R 15 5x 4.052 20.26
R 20 5x 3.94 19.72
R 30 5x 3.67 18.37
R 45 5x 3.37 16.87
♦
Dilution Sample
(microliters)
Blank
serum
(microliters)
10x 5 45
5x 20 80
3x 30 60
2x 50 50
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APPENDIX D
Intravenously administered albuterol concentration versus time profiles
for individual dogs
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APPENDIX E
Buccally administered albuterol concentration versus time profiles for
individual dogs
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APPENDIX F
Intravenously administered butorphanol concentration versus time
profiles for individual dogs
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APPENDIX G
Buccally administered butorphanol concentration versus time profiles for
individual dogs
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APPENDIX H
Statistical comparison between the disappearance rate constant for buccal
and intravenous drug administration
t-Test: Paired Two Sample for Means
P≤ 0.05
Albuterol IV Buccal
Mean 0.0019 0.0043
Variance 3.7E-07 4.3E-07
Observations 3 3
Pearson Correlation 0.739583
Hypothesized Mean Difference 0
df 2
t Stat -9.07115
P(T<=t) one-tail 0.005968
t Critical one-tail 2.919987
P(T<=t) two-tail 0.011936
t Critical two-tail 4.302656
t-Test: Paired Two Sample for Means
P≤ 0.05
Butorphanol IV Buccal
Mean 0.004033 0.002667
Variance 5E-06 1.03E-07
Observations 3 3
Pearson Correlation -0.99902
Hypothesized Mean Difference 0
df 2
t Stat 0.925388
P(T<=t) one-tail 0.226228
t Critical one-tail 2.919987
P(T<=t) two-tail 0.452457
t Critical two-tail 4.302656
105
VITA
Deirdre F. Vaughan
1373 Hampton Dr.
Auburn, AL  36830
(334)466-0394
vaughdf@auburn.edu
EDUCATION
Auburn University
College of Veterinary Medicine August 2000-present
DVM expected in May 2004
Texas A&M University
College Station, TX Sept. 1997-present
M.S. candidate in Veterinary Physiology
Auburn University
Auburn, AL       Sept. 1992-Dec. 1995
B.S. degree in Animal and Dairy Sciences
WORK EXPERIENCE
Dadeville Animal Clinic August 1994-present
Dadeville, AL
Veterinary Assistant
Auburn University May 2001-August 2001
College of Veterinary Medicine
Scott-Ritchey Research Center
Research Assistant
Texas A&M University Sept. 1997-August 1999
College of Veterinary Medicine
Clinical Pharmacology Laboratory
Graduate Research Assistant
